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Washington University in St. Louis, 2020 
Professor Scott J. Hultgren, Chair 
Urinary tract infections (UTIs) are one of the most prevalent infections, afflicting 15 
million women per year in the United States with annual healthcare costs exceeding $2-3 billion. 
Uropathogenic Escherichia coli (UPEC) are the main etiological agent of UTIs and employ 
numerous virulence factors for host colonization. The most common adhesive mechanism by 
which UPEC mediate host-pathogen interactions is the chaperone-usher pathway (CUP), which 
is responsible for the assembly of proteinaceous surface appendages termed pili. Generally, CUP 
pili function in adherence or invasion of host tissues and in biofilm formation on medical devices 
and body habitats. CUP pili are highly abundant and diverse among a wide variety of Gram-
negative pathogens, with 38 distinct pilus types in Escherichia species alone, mediating a 
considerable range of biological tropisms through adhesins at the distal pilus tip. Typically, these 
adhesins have a lectin domain, which recognizes a specific carbohydrate receptor, and a pilin 
domain to anchor the adhesin to the pilus. This thesis specifically examines the structural, 
dynamic, and allosteric properties of distinct E. coli CUP pilus adhesins that govern interactions 
critical for pilus function at the host-pathogen interface during UTI. 
 xii 
The type 1 pilus adhesin FimH is a critical virulence factor necessary for bacterial 
attachment to mannosylated receptors on the bladder epithelium during UTI. I determined 
through molecular and computational biophysics that FimH natively exists in a two-state 
conformational equilibrium in solution, composed of one low-affinity tense (T) and multiple 
high-affinity relaxed (R) conformations. I demonstrated that positively selected residues in FimH 
and ligand binding allosterically modulate this conformational equilibrium and that each of these 
conformational states engage mannose receptors through distinct binding modes. Mouse models 
of UTI indicate that FimH has evolved a “moderate” mannose binding affinity through a 
balanced conformational equilibrium to optimize persistence in the bladder during UTI. 
Furthermore, I discovered novel small-molecule galactoside antagonists that inhibit the FimH-
like adhesin FmlH from binding galactose-containing bladder and kidney epithelial receptors 
present during chronic UTI. Taken together, this thesis defines the biophysical basis of host 
receptor recognition and bacterial pathogenesis mediated by FimH and defines the atomic bases 
of distinct bacterial host tropisms mediated by FimH homologs, which were leveraged to spur 
the development of antibiotic-sparing, small-molecule glycomimetic antagonists as therapeutics 
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 Adhesive pilus fibers mediate the interaction between pathogens and specific host cell-
surface ligands that allow a pathogen to establish a foothold in a particular host tissue. The 
chaperone-usher pathway (CUP) constitutes one of the most prevalent mechanisms among Gram-
negative bacteria for the assembly of adhesive pili. Studies at the interface of genetics, 
biochemistry, and structural biology have detailed the functions of the chaperone and the usher, 
providing a step-by-step understanding of pilus biogenesis by this sophisticated molecular 
machine. Furthermore, studies have elucidated the molecular basis of host receptor recognition 
mediated by adhesins localized at the tips of CUP pili. Together, snapshots in CUP pilus assembly 
and CUP pilus-mediated host-pathogen interactions have unveiled necessary molecular details for 
the design and application of novel anti-virulence compounds that promise to prevent and treat 














One of the major pathways involved in assembly of adhesive pili in Gram-negative bacteria 
is the chaperone-usher pathway (CUP). CUP pili are thin, hair-like surface extensions involved in 
adherence and biofilm formation. One of the first observations of CUP pilus function was likely 
in 1908 when Guyot reported bacterial-mediated hemagglutination [1]. Since, significant 
improvements and discoveries have been made in the field of CUP pili revealing unique structural, 
biophysical, and biochemical phenomena of protein folding and assembly. Studies of CUP pili 
have exposed their crucial functions and essentiality in bacterial pathogenesis. CUP pili play 
critical roles in numerous infectious diseases, including type 1 pili in cystitis [2-6], S pili in 
neonatal meningitis [7, 8], F1 antigen in bubonic plague [9-11], and P pili in pyelonephritis [12-
15]. Piliated bacteria adhere to specific receptors on the host cell surface through CUP pilus tip-
localized adhesins. These adhesins are typically two-domain proteins comprised of a lectin 
domain, which recognizes a specific carbohydrate receptor, and a pilin domain to anchor the 
adhesin to the pilus. As many Gram-negative bacterial adhesins are assembled into polymeric 
surface appendages, CUP pili provide prevailing models for analysis and understanding of the 
assembly and function of a wide range of virulence associated proteins. CUP systems, particularly 
type 1 and P pili from uropathogenic E. coli, have been used as prototypes to elucidate how 
periplasmic protein monomers are assembled into complex structures and arrayed on the 
extracellular surface of Gram-negative bacteria without requiring cellular energy. In this chapter, 
I will focus on the structure, assembly mechanism, and receptor recognition mechanism of P pili 
and type 1 pili in uropathogenic Escherichia coli (UPEC), the most common cause of urinary tract 




CUP pili consist of multiple pilus subunits arranged into long, linear protein polymers. 
CUP pili can adopt one of two distinct pilus structures depending on the length of the G1 β-strand 
of the chaperone. F1-G1 long (FGL) chaperones assemble thin, fibrillary, amorphous structures 
while F1-G1 short (FGS) chaperones assemble thick, helical rods topped by a fibrillar tip [16]. 
CUP pili also vary according to usher relatedness across six major clades – α, β, γ(1-4), κ, π, and 
σ – of the 189-membered CUP pilus superfamily [16]. Paradigms for CUP pilus architecture and 
assembly have been well established with the P pilus and type 1 pilus of UPEC, members of the π 
and γ1 clades, respectively. These two archetypal pili exhibit a bipartite organization, consisting 
of a long, helical rod connected to a thin tip fibrillum. The P pilus subunits PapG, PapF, PapE, 
PapK, PapA, and PapH arrange in order from fibrillar tip to rod base (Figure 1). PapG, the adhesin, 
lies at the distal end of the pilus. The tip adaptor PapF connects PapG to the main tip component 
PapE, which appears in 5-10 copies and has a width of ~ 2 nm. The adaptor PapK anchors PapE 
to the main rod component PapA, which appears in >1000 copies and gives rise to a right-handed, 
helical structure that displays a 6.8 nm width, 2.5 nm pitch, and 3.3 subunits per turn [17-19]. 
Finally, PapH attaches at the base of the rod and terminates pilus biogenesis [20, 21]. Type 1 pili 
adopt a similar, yet condensed architecture [22]. The fibrillum consists of single copies of both the 
adhesin FimH and the tip subunit FimG, while the adaptor FimF links the fibrillum to the major 
rod component FimA, which appears in ~1000 copies (Figure 1). Preliminary studies suggest that 
FimI functions as the terminator subunit in type 1 pili [23, 24].  
 
Chaperone structure and function 
 CUP chaperones (~25-30 kDa) are all highly homologous in sequence and structure [25]. 
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They are composed of two complete Ig-like domains (Figure 2A). Chaperones function to 
transiently bind their cognate pilus subunits, shielding their interactive surfaces to facilitate their 
proper folding and stability in the periplasm [26]. In PapD, the chaperone from the P pilus system, 
a conserved salt bridge stabilizes the two Ig-like domains to adopt an overall boomerang-like 
shape. These domains orient to form a cleft that is directly involved in subunit binding. In the 
absence of subunits, chaperones like PapD and SfaE form dimers and Caf1M forms tetramers as a 
self-capping mechanism to prevent unfavorable interactions and proteolysis [27-29]. 
 Upon translocation of pilus subunits across the SecYEG translocase to the periplasmic 
space, they are taken up by their cognate periplasmic chaperones, which use several interactive 
surfaces to provide stability to the subunits. The active site of the chaperone is comprised of 
residues R8 and K112, a conserved basic patch in the cleft formed between the two domains. 
Mutagenesis of these basic residues abolishes the ability of the chaperone to mediate pilus 
assembly [30, 31]. Crystallography studies carried out on all of the P pili chaperone-subunit 
complexes [21, 32-36] further confirmed these interactions and the extended conformation by 
which the C-termini of subunits are anchored at the invariant R8 and K112 residues of the 
chaperone [31].  
 
Donor strand complementation (DSC) 
The absence of the seventh β-strand in the pilus subunit results in a deep groove on its 
surface that exposes its hydrophobic core. In a process termed donor strand complementation 
(DSC), the G1 strand of the chaperone is donated in trans in a non-canonical, parallel fashion to 
the exposed hydrophobic groove of the subunit to facilitate its proper folding [32, 37, 38] (Figure 
2B). The solvent-exposed set of alternating hydrophobic residues on the chaperone’s G1 strand 
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directly interact with subunit pockets [32]. In the case of PapD, residues L107, I105, and L103 are 
respectively in register with the subunits’ hydrophobic P1-P3 pockets. Mutating residue 105 is 
particularly detrimental to pilus biogenesis [27]. However, mutagenesis of residue L107 does not 
alter pilus assembly, which may be due to the plasticity of the P1 pocket [36]. These residues are 
termed P1-P3 residues based on their corresponding acceptor sites, the subunit P1-P3 pockets 
(Figure 2D). Additionally, N101 forms hydrogen bonds above the shallow P4 subunit pocket. 
Thus, the interactions involved in DSC facilitate subunit folding and prevent subunit aggregation. 
Presence of unfolded subunits in the periplasmic space otherwise induces periplasmic stress 
responses targeting aggregated subunits for degradation by the DegP protease [39, 40]. 
 
Donor strand exchange (DSE) 
            Once the subunit is folded, it remains bound to the chaperone until its incorporation into 
the pilus. The chaperone is exchanged for the N-terminal extension (Nte) of the incoming subunit 
via a “zip-in, zip-out” mechanism termed donor strand exchange (DSE). DSE is initiated by the 
insertion of the Nte P5 residue into the open P5 pocket of the previously assembled subunit (Figure 
2C-E). The chaperone G1 strand does not occupy the P5 pocket of subunits, which remains easily 
accessible in a chaperone-subunit complex to the P5 residue of the subunit Nte. Ultimately, 
insertion of Nte in an antiparallel fashion to the P2-P5 subunit pockets facilitates the removal of 
the chaperone’s parallel-oriented G1 strand. The DSE interaction is more energetically favorable 
than the DSC interaction, which allows DSE and the stable docking of subunits with each other to 




PapD-like chaperones have a set of conserved, solvent-exposed, hydrophobic residues 
(termed Set B: L32, Q34, T53, P54, P55, V56, R68, I93) situated at the N-terminal domain (Figure 
2A). X-ray crystallography studies demonstrated that the FimC chaperone of the type 1 pilus 
system interacts with the N-terminal domain of the usher via these Set B residues [42, 43], 
demonstrating that the Set B patch is a surface that interacts with the usher. Accordingly, point 
mutations in these residues negatively impact pilus biogenesis [27]. In addition, small molecules 
called pilicides, designed to block pilus biogenesis [44, 45], were shown to bind Set B residues 
and prevent the targeting of chaperone-subunit complexes to the usher [44]. These results implicate 
PapD’s conserved hydrophobic patch Set B as the usher-targeting site. Other chaperone residues 
that may be involved in interactions with other domains of the usher are subjects of investigation. 
Another set of highly conserved residues (Set C: L78, P79, D81, R82, E83, S84) is located 
at the elbow region of PapD, which is not known to interact with any protein partners. The stability 
of the chaperone depends on the formation of a buried salt bridge composed of D196, E83, and 
R116, which lies at the interdomain region [27]. E83 is part of the aspartate, arginine, glutamate, 
and serine (DRES) motif, which is highly conserved in the chaperone superfamily [25]. Situated 
at the end of the E1-F1 loop, part of the DRES motif packs against the hinge region connecting 
the two domains [25, 46], where the aspartate and arginine side chains from the DRES motif point 
out into solution, seemingly suitable for protein-protein interactions (Figure 2A). It is plausible 
that interactions with other proteins (subunits or usher domains) could cause conformational 
changes that would be transmitted to the interdomain region, possibly disrupting the salt bridge 
and thus facilitating a reorientation of the domains and causing allosteric conformational changes 




There are several major functional types of pilus subunits that may comprise a CUP pilus, 
including adhesins, adaptors, tip fibrillar subunits, pilus rod subunits, and terminators (Figure 1). 
Pilins, or pilus subunits, share an outstanding degree of sequence and structural homology with 
one another, necessary for preserving common mechanisms of subunit-subunit, chaperone-
subunit, and usher-chaperone-subunit interactions needed for maturation of a functional pilus. As 
described, the incomplete nature of the pilin fold ensures either chaperone binding (by DSC) or 
Nte binding (by DSE) to pilus subunits for their stability, proper folding, and ultimate 
incorporation into the growing pilus. Thus, the Nte, chaperone G1 strand, and the incomplete Ig-
like fold of pilin subunits, particularly the P1-P5 pockets, serve as common recognition motifs for 
the use of pilins as building blocks in the construction of a CUP pilus. However, structural 
distinctions across homologous pilins permit their unique positions and functions along the pilus 
chain. For example, differences in Nte sequence and hydrophobic pocket characteristics dictate 
subunit ordering. DSE reactions performed by incubating all combinations of Nte peptides (based 
on the five Nte-containing Pap subunits) with all chaperone-subunit complexes showed a range of 
reactivities [35, 47]. Reactions that occurred most rapidly were consistently those between cognate 
groove-Nte partners. In addition to chaperone-subunit and subunit-subunit interactions, subunits 
also contain specific surfaces that drive chaperone-subunit-usher interactions. Differences in 
subunit structure and residue side chains dictate selective trafficking to certain periplasmic 
domains of the usher. Thus, adhesin and terminator subunits, which occupy opposite ends of the 
pilus, adopt structures much more varied from their pilin counterparts required for their essential 
functions in host adhesion and pilus assembly termination, respectively.  
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Terminator structure and function 
 Studies in the Pap system suggest that pilus biogenesis ends with the incorporation the 
PapH terminator at the base of the pilus rod. Deletions or mutations of PapH result in the formation 
of long pili that are shed from the extracellular surface [20]. Overexpression of PapH results in 
short pili.  Further, the structure of PapD-PapH indicates that PapH has an occluded P5 pocket, 
which prevents the initiation of DSE with further subunits, thereby terminating pilus biogenesis 
[21]. Analogously, FimI may function as the terminator in type 1 pili [23, 24]. Further studies will 
elucidate whether incorporation of a P5 pocket-lacking pilin is utilized by other CUP pili for 
termination.  
 
Adhesin structure and function 
A mature CUP pilus typically contains an adhesin at its distal end. Adhesins contain two 
distinctive domains: a lectin domain, which functions to bind specific receptors with 
stereochemical specificity and contribute to host and tissue tropisms, and an Ig-like pilin domain, 
which links the receptor-binding lectin domain to the fibrillar tip [32, 48]. FimH and PapG, 
adhesins of the prototypical type 1 and P pilus systems, respectively, mediate host-pathogen 
interactions important in cystitis [5, 49-51] and pyelonephritis [14]. FimH mediates binding to α-
D-mannose-containing receptors whereas PapG binds galabiose, a receptor that is present in the 
globoseries glycolipids found in the kidney. Both lectin domains contain a β-barrel jelly-roll fold 
that is common to CUP adhesin structures, but they contain different receptor binding pockets. 
FimH contains a deep, negatively charged pocket at the tip of the lectin domain [52]. In contrast, 
PapGII (class II of three PapG classes, each of which recognize different globoseries of 
glycolipids) binds galabiose-containing receptors with a shallow binding pocket formed by three 
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beta strands and a loop at the side of the lectin domain [53]. CUP adhesins F17-G of ETEC [54] 
and GafD of UPEC [55] bind N-acetyl-D-glucosamine residues of proteins at a shallow binding 
site on the side of the lectin domain at a location unrelated to the binding pocket of PapG (Figure 
3). With the function of adhesion segregated to a distinct protein domain at the pilus tip, various 
bacterial strains can alter the structure and receptor specificity of the adhesin, thus allowing 
flexibility and selective advantage in establishing tropism.  
Numerous studies suggest that the lectin domain of FimH does not operate independently 
of the pilin domain but instead interacts intimately with it to influence receptor binding. A crystal 
structure of the type 1 pilus tip fibrillum [56] indicates a markedly different conformation in FimH, 
compared to the conformation observed in FimH in the FimC-FimH complex [48] or in the 
mannose-bound FimC-FimH structure [52]. In the tip structure, the pilin domain interacts with a 
compacted lectin domain in a stable, noncovalent manner, loosening the mannose-binding pocket 
at the distal end of the lectin domain and thereby inducing an inactive low-affinity state of the 
adhesin via a “page-turning” allosteric mechanism [56]. In contrast, FimH, when in complex with 
FimC and α-D-mannose, adopts an elongated, high affinity state [52], which was later shown to 
be induced by application of shear force, presumably by destabilization of inter-domain contacts. 
Indeed, cross-linking mutants along with positively selected residues in the pilin domain suggest 
that this conformational equilibrium is important for mannose binding and infectivity in murine 
models of cystitis [56, 57]. Shear force does indeed enhance bacterial adhesion to target cells [58], 
but whether this mechanism of tensile stress-induced binding enhancement applies to other pili 
systems or has a definitive role in pathogenesis remains to be seen.  
 
Usher domain function and selectivity 
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 The CUP usher catalyzes the translocation and assembly of the multi-subunit pilus fiber 
across the outer membrane, while maintaining membrane integrity. The usher is an outer 
membrane protein comprised of five domains: a 24-stranded beta barrel channel, plug, N-terminal 
domain (NTD) and C-terminal domains (CTD1, CTD2) [43, 59, 60]. In the apo state of the FimD 
usher, the plug resides in the lumen of the transmembrane channel, preventing flow of molecules 
across the outer membrane [61, 62]; in the active form, the plug swings away from the channel, 
creating an unobstructed opening through which pilins translocate (Figure 4). This plug switch 
induces a conformational change in the β-barrel domain, shifting the shape of the channel pore 
from ovular (52 Å x 28 Å) to nearly circular (44 Å x 36 Å) [63]. This in turn allows a range of 
subunit diameters (~20-25 Å) to pass through unobstructed. The plug then docks onto the NTD, 
as suggested in the crystal structure of the FimD usher [63] and from work in the Pap system [64]. 
The plug-NTD interaction results in the usher adopting an open state. 
 NTD and CTDs, which reside in the periplasmic space, serve as the workhorses of 
assembly within this molecular machine. Functional studies directly implicate the periplasmic 
domains of the usher in catalysis of pilus formation, as mutations in either NTD or CTD [59, 65] 
and deletions of the plug [62, 66] abrogate assembly. Measured relative affinities for the 
interactions of chaperone-subunit complexes with purified NTD, CTD2, and plug domains from 
the PapC usher suggest that (a) the tight-binding NTD serves as the initial anchoring site for the 
chaperone-adhesin complex, (b) plug or the NTD-plug complex serves as the docking site for all 
other chaperone-subunit complexes, and (c) CTD2 likely dissociates chaperone-subunits from 
NTD and plug, with the exception of the chaperone-terminator complex, which docks on plug or 
the NTD-plug complex and halts further pilus growth. Analogously to PapC NTD, the FimD NTD 
is selective; isothermal titration calorimetry (ITC) experiments show that FimD NTD binds the 
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chaperone when the chaperone is loaded with FimH or FimF but not with FimG or FimA [43]. 
Furthermore, these structures along with supporting NMR data reveal that the intrinsically 
disordered 24-residue N-terminal tail of NTD adopts an ordered conformation upon binding. As 
expected, deletion of the N-terminal tail of NTD completely abolishes pilus assembly in vivo [67]. 
In the ternary complex, the N-terminal tail of NTD contacts the chaperone and the subunit (FimH 
or FimF), constituting 50-60% of the total contact surface area (1260 Å2). While all components 
of these two ternary complexes adopt remarkably similar folds, there are subtle yet significant 
differences in hydrogen bonding at the FimD NTD-subunit interface that likely accounts for 
subunit selectivity. A similar molecular logic likely holds true for the selectivity of the NTD 
domains of other CUP ushers, although more work needs to be done to further bolster this 
argument. While the plug and CTD2 can recognize nearly all chaperone-subunit complexes, the 
mechanism by which this occurs remains undetermined. Similarly, the basis for the terminator’s 
ability to discriminate between plug and CTD2 remains unknown. More work is needed to 
elucidate the molecular basis of selectivity by usher domains for chaperone-subunit complexes to 
better understand the mechanism and subunit ordering of pilus assembly.  
 
Working model of usher-mediated pilus biogenesis 
 The results and associated interpretations presented above suggest the following working 
model of CUP pilus biogenesis (Figure 5): 
(1) The usher adopts a gated conformation in its inactive state, in which its plug domain 
lies in the center of the kidney-shaped β-barrel. NTD and CTD lie disordered in the periplasm, 
moving rapidly and randomly.   
 13 
 (2) Once NTD binds the initiator of pilus assembly, the chaperone-adhesin complex, the 
binding energy induces movement in the NTD linker that thereby transduces conformational 
changes in the β-barrel domain, relaxing its shape from ovular to circular and preventing plug from 
re-entering the channel lumen once it has already entered the periplasm. Concurrently, NTD may 
swing to transfer its bound chaperone-adhesin complex to CTDs. Once NTD has unloaded its 
cargo, it binds the now periplasmic plug domain to form the NTD-plug complex, which can then 
bind and dock other incoming chaperone-subunit complexes.  
 (3) Alternatively or concomitantly, the CTDs may swing over together to the NTD-plug 
complex to catalyze the dissociation of the chaperone-adhesin complex. A minor conformational 
species in the FimD-FimC-FimH complex as measured by electron paramagnetic resonance (EPR) 
[63] suggests the occurrence of an uncharacterized transient binding interaction between CTD2 
and the chaperone-adhesin complex that may mediate this transfer. With the chaperone-adhesin 
complex bound primarily to CTD1, the lectin domain of the adhesin lies in the channel lumen, and 
the NTD-plug complex is available for the incoming chaperone-tip subunit complex.     
 (4) Next, the NTD-plug complex recruits the upcoming chaperone-tip subunit complex, 
while the chaperone-adhesin complex is bound to the CTDs. A unique conformation in the NTD-
plug complex brings the tip subunit into the ideal orientation with respect to the adhesin for DSE, 
allowing for the assembly of the growing pilus fiber. The reaction results in the displacement of 
the chaperone off of the CTD, allowing the newly incorporated chaperone-subunit complex to 
dock on the CTDs. The process repeats for all chaperone-subunit complexes in order of the subunit 
ordering observed in the mature pilus fiber. 
 (5) Ultimately, the chaperone-terminator complex docks on the NTD-plug complex. 
Unable to bind CTD2 and unable to undergo DSE due to its lack of a P5 pocket, the chaperone-
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terminator complex signals the end of pilus growth. The plug may bind the chaperone-terminator 
complex with its βC, βB, βE, and βF side and swing into the β-barrel lumen with that same side 
facing the extracellular space, as seen in the apo state. The mature pilus fiber anchors to the outer 
membrane in this fashion and is ready to perform its adhesive function.  
 Overall, this model provides insight into how the usher assembles the CUP pilus. With 
domain affinities, molecular snapshots of pilus biogenesis steps, and genetic and biochemical 
evidence, we can now understand how the usher efficiently transfers chaperone-subunit complexes 
using its periplasmic domains to perform its catalysis of fiber growth. Further work will be required 
to gain a deeper mechanistic understanding of this molecular machine to provide knowledge of 
targetable protein interfaces and dynamic processes for next generation small-molecule pilicides 
that can inhibit these virulent adhesive pili. 
 
Role of CUP pili in infections 
 UPEC introduced to the urinary tract from the fecal flora is the leading causative agent of 
urinary tract infections (UTIs), responsible for 85% of community-acquired UTIs [68]. Genetic, 
biochemical, and imaging studies accompanied by murine models of UTIs revealed that CUP pili 
are crucial factors for causing this disease. For instance, type 1 pili, encoded by the fim operon, 
are required for bladder infection in a murine model of UTI [2-6] and for biofilm formation in rat 
kidneys [69]. The adhesin of type 1 pili, FimH, mediates binding to the mannosylated receptors 
on the surface of bladder urothelial cells for colonization and invasion of the superficial umbrella 
cells, which line the bladder lumen. Following invasion, UPEC grow inside the cytosol of host 
cells, giving rise to biofilm-like bacterial aggregates of 104-105 bacteria, known as intracellular 
bacterial communities (IBCs) [2, 6, 70]. Type 1 pili are required for the establishment and 
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maintenance of IBCs, allowing proliferation of UPEC, which upon maturation can detach and 
spread to neighboring urothelial cells to continue the infection cascade. As IBCs have also been 
observed in human patients suffering from UTIs [71], it is likely that involvement of type 1 pili 
and IBCs in human UTI is also common. Furthermore, dysbiosis of the gut microbiota after 
streptomycin treatment allows UPEC expressing type 1 pili and F17-like pili to colonize the 
gastrointestinal tract, the source reservoir from which UPEC emerge to infect the urinary tract 
[Spaulding & Hultgren Nature in press].  
 Another well-studied CUP system that is important in urinary tract infections is P pili, 
encoded by the pap operon. P pilus adhesin PapG was shown to be important in pyelonephritis in 
primate models of infection [14]. In rat models of infection, P pili were shown to enhance early 
colonization of the kidney tubular epithelium [69]. Most UPEC strains from human cases of 
pyelonephritis carry PapGII [72, 73], one of three classes of PapG, which binds to Galα1-4Gal 
receptor epitopes in the globoseries of glycolipids found in human renal tissue [53]. 
 In addition to P and type 1 pili’s importance in UTIs, various other CUP pili from different 
species are important in bacterial virulence. For instance, S pili, encoded by the sfa operon, is 
involved in meningitis [74, 75], while class 5 ETEC fimbriae are important for the initiation of 
diarrheal disease [76].  
 Conventionally, carriage of these CUP pili and other putative virulence factors has been 
considered the sole determinant of virulence among pathogens. However, recent comparative 
transcriptomic and phenotypic analyses among human uropathogens indicate that expression of 
CUP pili such as type 1 pili, and not their carriage, predicts colonization and virulence in the mouse 
bladder [77]. Additionally, differences in host susceptibility, inflammatory state, and infection 
history can alter tissue or host habitats to affect recognition by CUP pili, thereby modulating risk 
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of developing infectious disease, as observed in recurrent UTI [78]. Considering the importance 
of CUP pili in infection, understanding how these pili are assembled, the mechanisms by which 
they cause pathogenesis, and their genetic regulation is critical in disease prevention and 
development of novel therapeutics. 
   
CUP pili as anti-virulence targets  
 Antibiotics have led to significant improvements of human health over decades, improving 
quality of life and human longevity. However, antibiotic resistance is escalating [79] and multidrug 
resistant uropathogens are spreading globally [80]. Accompanied by a lack of a significant effort 
to develop novel antibiotics and the outstanding risk that antibiotic usage can negatively impact 
gut microbiota and result in opportunistic infections, the search for anti-virulence therapeutics is 
gaining attention. Due to the important role of CUP pili in bacterial virulence, they have been 
important targets for vaccine development studies as well as anti-virulence therapeutics. FimH was 
shown to be a successful vaccine option in both murine [81] and primate [82] models of infection. 
Keeping in mind the role of FimH in mediating adhesion with mannosylated uroplakin of 
uroepithelial cells, alky and phenyl-α-D-mannopyranosides, or mannosides, have been designed 
to competitively bind with FimH and interfere with adhesion on host cells. These mannosides not 
only block adhesion but also counteract internalization and in vitro/in vivo biofilm formation on 
biotic and abiotic surfaces [83, 84] (Figure 6A-B). Mannosides also potentiate the efficacy of 
existing antibiotics in a murine model of UTI and have great oral bioavailability, increasing hopes 
that they can be used in drug development [84]. Furthermore, mannosides specifically deplete 
UPEC residing in the gastrointestinal tract without affecting the resident microbiota, functioning 
as molecular scalpels that selectively remove virulent E. coli [Spaulding & Hultgren Nature in 
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press]. Similar to FimH, PapG was also a target for antivirulence therapeutics design such that p-
Methoxy-phenyl derivatives of galabiose inhibit PapG with low micromolar IC50 (half-maximal 
inhibitory concentration) values [85-88]. 
 In addition to targeting the receptor-binding site of the mature pilus, compounds that 
directly interfere with pilus biogenesis have also been developed. These rationally designed 
bicyclic 2-pyridone compounds, termed pilicides, inhibit UPEC hemagglutination of erythrocytes 
and biofilm formation by inhibiting both P and type 1 pilus biogenesis [44]. X-ray crystallography 
and biochemical studies revealed an interaction of these compounds with PapD [44, 45]. The 
pilicides were shown to bind with a conserved, hydrophobic, solvent-exposed patch at the N-
terminal side of the chaperone (Figure 6C-D), the presumed usher-binding site, thus explaining 
the structural basis of their mechanism of action. 
Translated to clinical practice, mannosides, pilicides, and vaccine options can be cost-
effective ways to prevent and treat UTIs and other infections that require CUP pili, while reducing 
antibiotic resistance. Using specific anti-virulence therapeutics should have minimal impact on the 
composition of host microbiota, reducing the risk of opportunistic or recurrent infections.  
 
Conclusion 
Gram-negative bacteria use the chaperone-usher pathway (CUP) to assemble virulent 
surface appendages called pili. Structural biology combined with genetic and biochemical 
approaches has elucidated crucial protein-protein interactions made by the dedicated chaperone 
and ushers to facilitate the ordered assembly of pilins into the final pilus structure on the 
extracellular surface. This work has generated new insights into protein folding and revealed novel 
mechanisms of macromolecular assembly. Chaperones stabilize the fold of each subunit in a 
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chaperone-subunit complex, in which the subunit is held in a high-energy conformation primed to 
participate in pilus assembly at the usher. Ushers catalyze pilus assembly through interactions with 
each chaperone-subunit complex, coordinating the release of the chaperone and interactions of 
subunits with each other as they fold into their final condensed structures and translocate through 
the outer membrane usher pore. Ultimately, assembled CUP pili display tip-localized adhesins to 
mediate key host-pathogen interactions required for virulence. These multi-disciplinary 
approaches have revealed snapshots of a sophisticated protein assembly machinery and 
mechanisms of adhesin binding, thus spurring the development of therapeutics that suppress 
infection in animal models. Together, these efforts will lead to a better understanding of CUP 
pilus-mediated infectious disease, giving rise to potent therapeutics that target acute, chronic, and 
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Figure 1. Architecture in P and type 1 pili. A graphic illustrating pili from the Pap (left) and 











Figure 2. Conserved chaperone residues, donor stand complementation, and donor strand 
exchange. (A) A ribbon diagram of the PapD-PapE complex. PapE (red) binds the N-terminal 
domain of PapD (green). The conserved surfaces of PapD are shown in a ball-and-stick 
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representation and highlighted in yellow, cyan, and orange. Their function is described in the text. 
(B) Donor stand complementation (DSC). The topology diagram on the left shows the secondary 
structure of donor strand complemented PapE (tan), indicating β-strands as arrows and α-helices 
as cylinders. PapD donates its G1 strand (green) parallel to the F strand of PapE. The ribbon 
diagram on the right also depicts DSC, in which the G1 strand of PapD (green) completes the fold 
of PapE (red). [PDB code: 1N0L]. (C) Donor strand exchange (DSE). The topology diagram on 
the left shows the secondary structure of donor strand exchanged PapE (tan), indicating β-strands 
as arrows and α-helices as cylinders. PapK donates its N-terminal extension (Nte, blue) antiparallel 
to the F strand of PapE. The ribbon diagram on the right also depicts DSE, in which the PapK Nte 
(blue) completes the fold of PapE (red). [PDB code: 1N12]. (D) The P1-P5 pockets of PapE. The 
surface representation of PapE (red) emphasizes the pockets that allow the PapK Nte (blue) and 
the PapD G1 strand (green) to mediate DSE and DSC, respectively. PapD residues L103, I105, 
and L107 (yellow, ball-and-stick representation) project into the P1-P3 pockets and are 
correspondingly referred to as P1-P3 residues. PapK Nte residues (cyan, ball-and-stick 
representation) project into the P2-P5 pockets and are correspondingly referred to as P2-P5 
residues. The N-terminal ends of the Nte and G1 strand are labeled in the corresponding color. 
Note the shallow nature of the P4 pocket, which only accommodates a glycine residue in the Nte 
sequence of Pap subunits, as shown in (E). (E) Sequence alignment of the PapD G1 strand and 
Nte’s of all Pap subunits (except PapG, which lacks an Nte). Pap subunits have conserved P2-P5 
residues at their Nte. P2, P3, and P5 residues are hydrophobic (blue), while the P4 residue is strictly 
glycine (yellow) to prevent steric clashes with the shallow P4 binding groove. PapD has three 
hydrophobic residues that correspond to the P1-P3 residues. The arrows indicate the N- to C-
terminal direction for the sequences of Pap subunits (blue) and PapD (green).  
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Figure 3. Co-crystal structures of CUP adhesins with their receptors. (A) FimH in complex 
with D-mannose [PDB code:1KLF] (B) PapG in complex with galabiose [PDB code: 1J8R] (C) 
F17-G in complex with N-acetyl-D-glucosamine [PDB code: 1O9W] (D) GafD in complex with 
N-acetyl-D-glucosamine [PDB code: 1OIO] In every complex, the adhesin (magenta) is shown as 
a ribbon representation (left) and a magnified surface representation (right), with the bound ligand 
depicted as a ball-and-stick representation (green). The structures demonstrate that the binding 
pocket is in different locations of the adhesin fold and has different morphology, which dictates 





Figure 4. Structures of the gated and open FimD usher. (A) In the gated apo state, the plug 
(blue, surface representation) resides in the lumen of the usher pore (orange, ribbon diagram), 
preventing flow of molecules across the OM and maintaining membrane integrity. The remaining 
usher domains are not depicted since a FimD truncate was used to solve the apo structure [PDB 
code: 3OHN] (B) In the FimD-FimC-FimH complex, the plug swings into the periplasm and binds 
NTD (light blue), while FimC (green) docks at CTD1 (yellow) and CTD2 (purple) with its bound 
FimH (magenta). The lectin domain of FimH now resides in the lumen of the usher. Note the 
unoccupied P5 pocket (light pink) in the FimH pilin domain, which is targeted by the Nte of the 
incoming subunit FimG for DSE [PDB code: 3RFZ]. Rotation of the usher by 90°, such that the 
 29 
usher is seen from the top, shows a kidney-shaped pore in the plug-gated usher but a nearly circular 


















Figure 5. Model of pilus assembly. Upon translocation of subunits into the periplasm via the SEC 
machinery, chaperone proteins bind the subunits to maintain their proper fold and stability. At the 
outer membrane, the usher lies in a gated state, with the plug domain (blue) residing in the lumen 
of the usher pore (orange). Once the chaperone-adhesin complex binds the usher NTD (cyan), the 
plug domain swings away from the pore and docks onto the NTD, thus preparing the usher for 
pilus secretion. Soon thereafter, CTD1 (yellow) and CTD2 (purple) may swing over to bind and 
carry the chaperone-adhesin complex, freeing the NTD-plug complex in the process. The freed 
NTD-plug complex recruits the incoming chaperone-subunit complex, orienting it properly so that 
the Nte can participate in DSE with the CTD-docked chaperone-adhesin complex and the newly 
exchanged chaperone-subunit complex can transfer to the CTDs. The process repeats until the 
chaperone-terminator complex, bound at the NTD-plug complex, cannot transfer to the CTDs or 
engage in DSE, signaling the end of pilus assembly.  
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Figure 6. CUP pili as antibacterial targets. (A) Crystal structure of a mannoside (cyan) in 
complex with the FimH lectin domain (magenta) [PDB code: 3MCY]. (B) Mannoside prevents 
IBC formation and can treat established infections [84]. Confocal microscopy of mice bladders 
depicts an intracellular bacterial community (IBC, green) in the left panel and prevention of IBC 
formation with mannoside treatment in the right panel (white arrows indicate luminal bacteria). 
(C) Crystal structure of a pilicide (cyan) bound to PapD (green). The pilicide binds to the F1, C1 
and D1” strands, a region thought to be the usher-targeting site of the protein, where many of the 
Set B residues coincide [PDB code: 2J7L]. (D) Pilicide inhibits type 1 pilus and P pilus assembly. 
Atomic force microscopy images show a piliated, untreated bacterium (left panel) and a naked, 
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pilicide-treated bacterium (right panel), indicating that pilicides suppress pilus biogenesis. Figure 
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Positive selection in the two-domain type 1 pilus adhesin FimH enhances Escherichia 
coli fitness in urinary tract infection (UTI). We report a comprehensive atomic-level view of FimH 
in two-state conformational ensembles in solution, composed of one low-affinity tense (T) and 
multiple high-affinity relaxed (R) conformations. Positively selected residues allosterically 
modulate the equilibrium between these two conformational states, each of which engages 
mannose through distinct binding orientations. A FimH variant that only adopts the R state is 
severely attenuated early in a mouse model of uncomplicated UTI but is proficient at colonizing 
catheterized bladders in vivo or bladder transitional-like epithelial cells in vitro. Thus, the bladder 
habitat has barrier(s) to R state-mediated colonization possibly conferred by the terminally 
differentiated bladder epithelium and/or decoy receptors in urine. Together, our studies reveal the 
conformational landscape in solution, binding mechanisms, and adhesive strength of an allosteric 


















Bacterial pathogens adhere to and establish footholds in favorable habitats within their 
host. Adhesion often confers fitness advantages to bacterial pathogens by promoting access to 
essential nutrients, resistance to displacement by fluid flow, or evasion of immune responses [1-
3]. Bacterial pathogens have evolved numerous ways in which to achieve adhesion either 
specifically or nonspecifically through extracellular structures that include capsules, extracellular 
polymeric substances, pili/fimbriae, flagella, and other diverse adhesins [1, 4, 5]. Many of these 
adhesive virulence mechanisms figure prominently in the colonization of the bladder by 
uropathogenic Escherichia coli (UPEC), which account for approximately 85% of all urinary tract 
infections (UTIs) [6,7]. Mouse models have shown that adhesive hair-like surface appendages 
called type 1 pili allow UPEC to colonize the bladder epithelium during UTIs by binding to 
mannosylated receptors on the urothelial surface through the tip-localized adhesin FimH [8]. 
Clinical observations and mouse models of UTI have shown that FimH mediates the invasion of 
UPEC into bladder superficial umbrella cells via endocytosis [9-12]. Escape from the endocytic 
vesicle allows UPEC to replicate within the cytosol to form intracellular bacterial communities 
(IBCs), which is one mechanism used by UPEC to subvert neutrophil attack, thus facilitating 
survival and dissemination during UTI [9-12]. 
Consistent with its vital role in bacterial colonization of the bladder, FimH has evolved 
within human uropathogenic strains of E. coli by positive selection [13]. FimH is composed of the 
following: (i) an N-terminal lectin domain (FimHLD) that binds mannose via a pocket formed by 
three loops, (ii) a C-terminal pilin domain (FimHPD) that noncovalently joins FimH to the pilus tip, 
and (iii) a five–amino acid linker that connects the two domains (Fig. 1A). It has been shown that 
three positively selected residues (residues 27, 62, and 163), which lie outside the mannose-
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binding pocket, modulate conformational changes in FimH (Fig. 1B) [14]. Crystal structures of 
FimH in various stages of pilus assembly have revealed that FimHPD exists in one conformation 
but FimHLD has at least two conformational states that show distinct affinities for mannose (Fig. 
1B) [15-19]. Before pilus assembly, the incomplete immunoglobulin (Ig)–like fold of FimHPD is 
stabilized via a donor strand complementation interaction with the chaperone FimC in the 
periplasm [15, 20]. Crystal structures have revealed that FimH adopts an elongated conformation 
when bound to FimC, wherein FimHLD and FimHPD do not interact with each other and FimHLD is 
in a high-affinity mannose-binding state. Thereafter, the FimC-FimH (FimCH) complex initiates 
pilus assembly at the outer membrane, where the FimD usher catalyzes donor strand exchange 
(DSE), in which the N-terminal extension (Nte) of FimG displaces FimC to complete the Ig-like 
fold of FimHPD [21-23]. Crystal structures show that FimH adopts a compact conformation when 
bound to FimG, wherein FimHLD and FimHPD interact closely with one another and 
FimHLD adopts a low-affinity mannose-binding state. To succinctly describe the correlation 
between all the structural and functional properties of FimH in its two known conformations (Fig. 
1B), we adapted the nomenclature used in the Monod-Wyman-Changeux model of allostery to 
herein refer to the high-affinity conformation as the relaxed (R) state and the low-affinity 
conformation as the tense (T) state. On the basis of these structures, an allosteric model that links 
the conformation of FimH to its mannose-binding function has been proposed (Fig. 1C) [17, 24]. 
This model posits that FimHPD can allosterically diminish the ability of FimHLD to bind mannose 
through interactions with the base of FimHLD. Conversely, mannose binding to FimHLD appears to 
promote FimHLD conformations that no longer interact with FimHPD. However, the structural and 
evolutionary basis for conformational allostery in FimH at the pilus tip remains incompletely 
understood. Here, we characterize the conformational ensembles, dynamics, and binding 
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mechanisms of FimH variants in a tip-like setting in solution. We discovered a mechanism 
whereby positively selected residues allosterically modulate a two-state conformational 
equilibrium in FimH to adapt a “moderate” mannose-binding affinity for optimal colonization of 
the bladder during UTI. 
Results 
FimGNteH functions as a type 1 pilus tip-like setting 
Biophysical experiments to directly probe conformations of FimH within an in vitro 
reconstituted pilus tip have remained challenging because of the inherent tendency of pilus 
subunits, or pilins, to self-polymerize and introduce heterogeneity in solution [14]. Thus, we 
created a “minimal” tip-like FimH complex through a spontaneous in vitro DSE reaction between 
FimH and a peptide corresponding to the Nte of FimG (FimGNte, residues 1 to 15) (Fig. 2A). This 
strategy was based on previous work that demonstrated how Nte peptides stabilize pilin domains 
[22]. We investigated the conformational and functional effects of allelic variation in positively 
selected residues A27, A62, and V163 [13, 14] on FimH within the FimGNteH complex. This was 
done using the FimH sequence of the UPEC strain UTI89 [25] as the wild-type (WT) background. 
We produced FimGNteH complexes with WT and variant FimH sequences (A62S, A27V/V163A) 
and the Q133K variant, a binding pocket mutation that abrogates adhesion [13]. As with other DSE 
interactions [14], all purified FimGNteH complexes exhibited high stability because all FimH 
variants remained bound to FimGNte in the SDS sample buffer at room temperature (~31 kDa) but 
dissociated when boiled (~29 kDa) (Fig. 2B). Moreover, these variant FimGNteH complexes 
displayed the same differential binding affinities toward human mannosylated glycoproteins as 
those affinities previously determined by equilibrium binding analysis of FimCGH variants (Fig. 
2C): A62S shows low affinity, WT displays intermediate or moderate affinity, and A27V/V163A 
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exhibits high affinity for mannose. However, each of the binding-competent FimH variants 
displayed equal affinity for mannose when in a FimCH complex [14]. Thus, we hypothesize that 
the observed adhesive differences among FimGNteH complexes are the result of shifts in 
conformational equilibria of FimH in a tip-like setting caused by sequence variation. In summary, 
the FimGNteH complex reliably functions as a minimal tip-like setting and appears well suited for 
the examination of FimH conformation by molecular biophysics. 
Crystal structures of ligand-free FimGNteH variants reveal diverse conformations in a tip-like 
setting 
Apo x-ray crystal structures of FimGNteH A62S and FimGNteH A27V/V163A were solved 
at 1.96 and 2.6 Å resolutions, respectively, to investigate whether conformational changes 
determine the differences in mannose affinity of FimH in a tip-like setting. Both structures were 
solved by molecular replacement (MR) using FimHPD and either the low-affinity or high-affinity 
FimHLD from previously solved crystal structures as search models (table S1). The FimGNteH 
A62S crystal structure reveals four FimGNteH copies in the unit cell (fig. S1A), each adopting 
a T conformation (Fig. 2D). This T conformation is nearly equivalent to the T conformations of 
FimH (from E. coli strain F18) observed in (i) a FimCFFGH crystal structure [17] and (ii) the apo 
and heptyl mannoside–bound FimGNteH crystal structures (fig. S2) [26]. In these structures, 
FimHLD adopts the same overall compacted shape, widened β-sandwich fold, and displaced 
binding loops that confer weak affinity for mannose (fig. S2). However, structural alignment of 
FimHPD in the FimGNteH A62S complex to FimHPD from the WT complexes in 
the T conformation exposes a ~7 Å rigid-body tilt of FimHLD, suggesting a small vibrational 
degree of conformational flexibility in the T state. Despite this tilt, the T conformer of FimGNteH 
A62S forms the same FimHPD-FimHLD interface, in which hydrophobic interactions and 
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interdomain hydrogen bonds bury the linker and an “insertion loop” (residues 109 to 124) [17] 
within a local hydrophobic core (Fig. 2E). Moreover, three of the four FimGNteH A62S copies lack 
visible electron density in regions of mannose-binding loop 1 (residues 11 to 16), particularly at 
residues 13 and 14, suggesting that loop 1 is highly dynamic within the crystal (fig. S1B). 
In contrast, the crystal structure of FimGNteH A27V/V163A reveals a novel 
R conformation, wherein the orientations of the FimHLD and FimHPD form a 90° bend (Fig. 2D). 
This observed conformation represents a substantial structural deviation from the elongated 
orientation of FimHLD and FimHPDobserved in the R conformation of FimH bound to the FimC 
chaperone; thus, we refer to this crystal structure as the bent R conformation and the previously 
identified chaperoned state as the elongated R conformation [15]. This bent R conformation is 
also distinct from a recently solved crystal structure of FimFNteH bound to heptyl mannoside, 
which shows FimHLD adopting a ~45° bend angle and a different orientation with respect to 
FimHPD (fig. S2) [26]. Structural alignment of FimHLD’s of the bent and elongated 
R conformations indicates that the FimHLD’s of the two R structures are nearly identical [root 
mean square deviation (RMSD) = 0.6 Å], displaying the same binding loop and side-chain 
orientations that are required for high-affinity interactions with mannose (Fig. 2F) [16]. 
Furthermore, the bent conformation exhibits a new interface between FimHLD and FimHPD, 
composed of a dislodged insertion loop and an extended, solvent-exposed linker (Fig. 2E). No 
specific hydrogen bonding, electrostatics, or hydrophobic interactions are observed at this new 
interface, which would allow for a high degree of conformational flexibility in the relative 
orientations between FimHLD and FimHPD about the extended linker. Instead, multiple contacts 
formed between symmetry partners within the crystal lattice are coordinated by Ca2+, which likely 
allowed for crystallographic trapping of the elusive bent R conformation (fig. S1, C and D). 
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Comparison of the bent R conformation to the T conformation indicates that the orientation of 
FimHLD and FimHPD in the bent R conformation lies on a different bend and rotation axis than 
their orientation in the T conformation, hinting at considerable conformational freedom and 
possible transition pathways between T and bent/elongated R states. Together, these two FimH 
conformations (T and bent R) provide the first atomic-level description of a functionally diverse 
structural ensemble adopted by FimH in a native tip-like setting in the absence of ligand. 
Positively selected residues and ligand binding modulate conformational ensembles of 
FimGNteH variants 
Structural ensembles of FimH in solution were probed by small-angle x-ray scattering 
(SAXS) of FimH variants in FimGNteH or FimCH complexes. In a FimCH complex, all binding-
competent FimH variants have the same affinity for mannose [14]. They also appeared to adopt 
the same high-affinity elongated R conformation based on the structural comparison heat map 
(χ2 = 0.4 to 0.6) (fig. S3, A and B) and rigid-body modeling of the FimCH crystal structure to the 
SAXS profiles for each of the FimCH variants (χ = 0.9 to 1.3) (fig. S3C). In contrast, each of these 
FimH variants had a drastically different affinity for mannose when in complex with FimG (Fig. 
2C) [14]. Correspondingly, in the FimGNteH complex, each variant adopted very different relative 
conformation(s) (χ2 = 0.6 to 7.4), with the low-affinity A62S and high-affinity A27V/V163A 
variants being most dissimilar from one another (Fig. 3A). Further, radius of gyration (Rg) and 
maximal intramolecular distance (Dmax) measurements indicated that A27V/V163A FimH is larger 
in overall shape by ~2 Å and more extended by ~5 Å than all other tested variants (Fig. 3B). Thus, 
we propose that positively selected residues allosterically influence the conformation(s) of FimH 
in pilus tips in solution, thus modulating mannose-binding affinity. 
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To resolve the solution structure(s) of FimH variants in a tip-like setting in the absence or 
presence of 4Z269, we evaluated the agreement between SAXS profiles and crystal structures of 
FimGNteH in four distinct conformations [T, bent R, a previously identified distinct bent R [26], 
and elongated R] either individually or in combination with one another. Rigid-body modeling of 
individual structures [28] against these scattering profiles resulted in moderate-to-poor goodness 
of fit (χ = 2 to 10) (fig. S3D). In contrast, multistate rigid-body modeling determined specific 
weighted combinations of multiple conformational models that fit the data better than any 
individual model. This analysis indicated that in the absence of 4Z269, the A27V/V163A variant 
exists entirely in the R state, comprising a mix of elongated and bent shapes, whereas WT, 
Q133K, and A62S adopt various proportions of T and bent R states (fig. S3E). Addition of 4Z269 
shifted the equilibrium away from the T conformation and toward a mix of bent and elongated 
R conformations for all variants except Q133K. However, multistate rigid-body modeling of 
SAXS profiles for FimGNteH WT and A27V/V163A variants in the presence of 4Z269 resulted in 
moderate goodness of fit, which indicates that the four abovementioned static conformations do 
not completely represent the solution ensemble and implies additional solution conformations that 
have not been determined by crystallography. Together, the improvements in goodness of fit from 
multistate modeling strongly intimate a conformational equilibrium and suggest that the crystal 
structures used in rigid-body modeling likely represent conformational snapshots and may not 
necessarily represent “preferred” states or capture the expanse or diversity of the conformational 
space of FimH in solution. In agreement with the multistate modeling, differential scanning 
fluorimetry revealed a two-state unfolding behavior for apo FimGNteH WT, Q133K, and A62S, 
with shifts toward one-state unfolding for A62S and WT variants in the presence of 4Z269 (fig. 
S3F). Single-state unfolding was observed for FimGNteH A27V/V163A in the presence and 
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absence of 4Z269. Together, these data strongly suggest that the identity of positively selected 
residues and mannose binding allosterically influence a preexisting equilibrium of distinct 
conformations in FimH in solution. 
Further, ion mobility–mass spectrometry (IMMS) was used as a direct method to 
investigate conformational distributions of FimH due to the ability of IMMS to resolve protein 
collision cross sections (CCSs). All FimGNteH and 4Z269-bound FimGNteH complexes remained 
intact when they were electrosprayed into the mass spectrometer, facilitating downstream analysis 
of the tip-like setting by IMMS (fig. S4, A and B). The CCS distributions at low collision energy 
(CE) of the WT, Q133K, and A62S variant FimGNteH complexes revealed a major peak and 
shoulder, whereas only one predominant peak with positive skew was observed for the 
A27V/V163A variant (Fig. 4A). Comparison of these distributions indicated that the 
A27V/V163A distribution is shifted to the right (or “right-shifted”) and displays a greater mean 
CCS than do the other variant distributions, consistent with its larger average shape 
(by Rg and Dmax) in solution. Given their non-normal shape, these distributions were modeled as a 
sum of two Gaussian curves. The WT, Q133K, and A62S FimGNteH complexes were each 
similarly best explained by two curves that have mean CCS values of 2464 to 2472 Å2 and 2606 
to 2636 Å2, which we respectively label A and B (Fig. 4B and table S2). In contrast, the 
A27V/V163A FimGNteH profile was best explained by two highly overlapping curves with mean 
CCS values of 2480 and 2565 Å2, which we respectively label A and C given their positions 
relative to the curves assigned for the other three FimH variants. Binding of 4Z269 caused a 
rightward shift in the overall CCS distributions of WT, A62S, and A27V/V163A (Fig. 4B). 4Z269-
bound WT and A62S FimGNteH displayed CCS distributions with right-shifted A and right-
shifted B, indicating that the two major structural species can engage 4Z269. In contrast, 4Z269-
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bound A27V/V163A FimGNteH displayed a normal CCS distribution adequately explained by one 
well-fitting curve because modeling with two Gaussian curves indicated that right-
shifted A and C overlap too extensively for an unambiguous assignment. As expected, no 
FimGNteH Q133K:4Z269 complex was observed (fig. S4B). In all cases, CCS distributions steeply 
increased with elevation of CE, indicative of protein unfolding and confirming that the CCS 
distributions analyzed above represent folded protein conformations (fig. S4C). In summary, 
FimGNteH WT, Q133K, and A62S in the gas phase take on an equilibrium of two distinct 
conformations with partially overlapping CCS distributions, whereas FimGNteH A27V/V163A 
adopts an equilibrium of two very similar conformations with highly overlapping CCS 
distributions. Thus, we have resolved two to three different structural conformations among 
FimGNteH variants in the gas phase. However, the width of the measured CCS distributions and 
mixture of structural populations likely mask multiple underlying conformational substates that 
dynamically interconvert within this conformational landscape. The conformational states 
represented by peaks A, B, and C may relatively correspond to bent R, T, and elongated R states, 
respectively, but a detailed examination of the presumed conformational dynamics of 
the T and R states is necessary to assess the validity of these structural assignments. 
FimGNteH samples expansive conformational phase space composed of restrained T state and 
dynamic R state 
To gauge the dynamic behavior of FimH in the FimGNteH WT tip-like setting, we 
performed unrestrained molecular dynamics (MD) simulations in four replicates, each starting 
from the T, bent R, and elongated R conformations in the presence or absence of ligands. MD 
trajectories initiated from the T state revealed very little structural fluctuation (RMSD) over time, 
vibrating around a fixed protein shape (Rg distribution), whereas those initiated from the bent 
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R state carved a vast conformational landscape with various overall protein shapes (Fig. 5A and 
movies S1 and S2). To best compare and conceptualize the sampled conformational landscapes, 
we parameterized FimGNteH conformation within a phase space composed of three measurable 
angular dimensions: (i) bend, (ii) twist, and (iii) orientation of FimHLD relative to FimHPD (fig. 
S5A). This analysis showed the breadth of conformations sampled in the R state compared to the 
restrained phase space of the T state simulations (Fig. 5B). Motions among the R conformations 
resembled movement about a ball-and-socket joint, in which a wide range of bends and rotations 
are accessible but restrained by the architecture of the FimHLD and FimHPD interface, which 
functions as a “socket.” We also observed considerable overlap in phase spaces from simulations 
initiated from the bent and elongated R states (Fig. 5B and movies S2 and S3), but no exchange 
between T and R states under these in silico conditions or in preliminary trials at 200 to 600 ns, 
suggesting a high-energy barrier to transition between T and R states that occurs on a much longer 
time scale (microseconds to milliseconds). Thus, the bent and elongated R conformations 
represent distinct snapshots of a highly dynamic conformational state, whereas the T conformation 
is a snapshot of a conformationally restrained structural state, which argues for enthalpy-entropy 
compensation in the equilibrium between T and R states. 
Dynamics and binding mechanisms of conformational populations in FimGNteH WT 
Mannose was then included in simulations of FimGNteH WT to probe its effect on 
conformational dynamics and mechanisms of ligand binding. The presence of mannose did not 
significantly alter the simulated dynamic behaviors of the T and R states (Fig. 5C and movies S4 
to S6). Strikingly, the R states remained bound to mannose even during the bending, twisting, and 
rotation that occured between the two domains throughout the duration of the simulations (Fig. 
5C and movies S5 and S6). As expected, the R states oriented their binding pocket loops to clasp 
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mannose tightly with rare, short-lived dissociation events, a signature of high-affinity binding (Fig. 
5, C and D). Mannose sat in the R pocket rigidly in a “horizontal” orientation, held in place by 
hydrogen bonds to residues in loop 2 (N46 and D54) and loop 3 (Q133, N135, and D140) and 
through packing against I13, I52, and the “tyrosine gate” (defined as binding pocket residues Y48 
and Y137), as previously observed [16]. In contrast, T states weakly interacted with mannose, 
characterized by continual motion of mannose within the open T pocket and multiple, long-lasting 
dissociation events (Fig. 5C and movie S4). When bound to the T state, the mannose ring 
occasionally sampled the horizontal orientation, as observed in the pocket of the bound R state, 
but was primarily observed rotated ~45° relative to its horizontal orientation (Fig. 5D). In 
the T state pocket, the hydroxyl group off the achiral carbon (C6) of mannose was bound to the N 
terminus of FimH and the carboxyl side chain of FimH residue D54. These two interactions were 
also observed with mannose bound to FimH in the R state. In contrast to what was observed in 
the R state, the axial hydroxyl group off the mannose anomeric carbon (C1) faced away from the 
rest of the binding pocket. This “tilted” mannose orientation represents a unique bound 
conformation and provides the first mechanistic insights into how the T state may contribute to 
host-pathogen interactions. FimH engages complex mannose-containing glycans on glycoproteins 
expressed on host epithelial cells [29, 30]. Thus, to have biological significance, the tilted mannose 
orientation must allow stereochemical space for FimH to engage the mannose-containing glycan 
without steric clashes with the extended glycan chain. Simulations indicated that oligomannose-3 
(Man(α1–3)-[Man(α1–6)]-Man) approached and bound the T state pocket in either the tilted or 
horizontal orientation with about equal frequency, revealing the sterically unhindered manner in 
which the T state can engage oligomannose receptors (Fig. 5, E and F, and movie S7). As expected, 
oligomannose-3 bound to the R state only sampled the horizontal orientation (Fig. 5, E and F, and 
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movie S8). Docking of oligomannose-3-chitobiose (Man(α1–3)-[Man(α1–6)]-Man(β1–4)-
GlcNAc(β1–4)-GlcNAc) to distinct time points within the T state simulations indicated that the 
1–3 branched terminal mannose of the oligomannose epitope is capable of freely rotating by ~45° 
within the binding pocket to allow for intercalation of the Man-GlcNAc moiety within the 
sterically accessible, dynamic tyrosine gate (fig. S5B). Previous crystallographic studies and 
isothermal titration calorimetry experiments indicate that the tyrosine gate displays a high degree 
of conformational dynamics in the presence of hydrophobic functional groups, such as those within 
the aglycon moiety of mannosides [31]. Thus, the proposed ligand entry and rotation pathways 
may represent a stepwise mechanism through which induced-fit binding proceeds, whereby 
interactions in the T state trigger structural perturbations within FimHLD that culminate in T-
R conformational changes. 
Comparison of the distributions of binding loop and residue positions among apo T, 
mannose-bound T, apo R, and mannose-bound R states for WT FimGNteH revealed specific 
motions that are correlated with mannose binding (fig. S5C). Among these changes, movement of 
loop 1 toward the binding pocket was most strikingly associated with mannose binding in 
the R state but marginally so in the T state. Despite the occasional displacement of loop 1 away 
from the R pocket, mannose often remained stably associated with R, suggesting that loop 1 
positioning is not the only determinant of mannose binding. Consistent with this observation, 
binding assays performed on loop 1 deletion mutants and chimeras in WT FimHLD showed a 
significant reduction, but not total abrogation, in mannose binding, demonstrating a role for loop 
1 as an affinity clamp in mannose recognition (fig. S5D). These findings agree with the weakened 
mannose affinity observed in mutations upstream of loop 1 that prevent β-hairpin formation 
necessary to bring loop 1 in close proximity to the binding pocket and observed in a recent 
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cocrystal structure showing loop 1 in close proximity to heptyl mannoside in a bound T state due 
to stabilization from crystal packing [26, 32]. In all, these computational studies establish a vast 
conformational phase space in the absence of ligand characterized by a conformationally 
restrained T state and multiple, shape-shifting R state conformations, and they elucidate structural 
and dynamic insights into two distinct mechanisms of mannose recognition by the low-
affinity T and high-affinity R conformations. 
Positive selection in FimH promotes moderate mannose-binding affinity to facilitate bladder 
colonization 
Positively selected residues, which were identified through sequence analysis of FimH 
alleles enriched in urinary E. coli isolates, significantly affect adhesive function and bacterial 
fitness in the urinary tract [13]. Despite A27V/V163A existing entirely in the high-affinity R state, 
previous work paradoxically demonstrated that UTI89 engineered to encode FimH A27V/V163A 
in place of FimH WT was severely attenuated and unable to form IBCs in the C3H/HeN mouse 
model of UTI at 6 to 24 hours post-infection (hpi) [13, 14]. We investigated the kinetics of this 
virulence defect during the acute stages of bladder colonization. UTI89 expressing A27V/V163A 
FimH exhibited attenuated colonization as early as 1 hpi, which suggests a defect in the ability of 
A27V/V163A to bind and/or invade superficial facet cells (Fig. 6A). Yet, UTI89 expressing 
A27V/V163A FimH bound and invaded 5637 bladder cells in vitro more efficiently than UTI89 
expressing WT FimH (Fig. 6, B and C), suggesting that the high-affinity variant does not lack the 
capacity to bind bladder tissue per se. 5637 bladder cells, a cancer cell line, exhibit more 
similarities with undifferentiated transitional bladder epithelial cells than with the terminally 
differentiated superficial facet cells that line the undisrupted bladder lumen [33]. Thus, attenuation 
in the mouse model may reflect colonization resistance properties of the bladder habitat that are 
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specifically selective against A27V/V163A FimH over WT FimH. To address this hypothesis, we 
changed the bladder habitat by inserting a catheter implant and subsequently tested these FimH 
variants in a model of catheter-associated UTI (CAUTI). In this model, a 5-mm piece of silicon 
tubing is implanted into the C57BL/6 mouse bladder, which mechanically disrupts regions of the 
bladder epithelium, exposing the underlying transitional epithelium and inducing inflammation. It 
has previously been shown that this catheterization increases the efficiency of bladder colonization 
by otherwise attenuated species of bacteria [34-37]. In the absence of an implant, again, a 
colonization defect was observed in C57BL/6 mice at 24 hpi (Fig. 6, D and E). Within this CAUTI 
model, in the presence of an implant, UTI89 with either WT or A27V/V163A FimH robustly 
colonized both the implant and the implanted mouse bladder tissue at 1 day after infection, 
although this rescue was partial because WT still outperformed A27V/V163A by 10-fold in 
bacterial titers in the bladder (Fig. 6, D and E). How the implant facilitates colonization may be 
multifactorial. First, disruption of the terminally differentiated epithelium may allow bacteria 
expressing the A27V/V163A variant to bypass the intact superficial facet cell layer and colonize 
deeper epithelial layers. Second, the catheter provides another surface to which the bacteria can 
bind and form a “staging ground” for dissemination to the bladder tissue. This is particularly 
possible because implanted catheters become coated by host proteins, including THP [36, 38], 
which we have shown is tightly bound by A27V/V163A (Fig. 2C). In addition, A27V/V163A can 
directly interact with implanted catheters, and in vitro assays indicate that it forms biofilms on 
abiotic surfaces to a higher degree than does WT [13]. In contrast, without the catheter, the tighter 
binding to soluble THP, or other soluble host proteins or mannose-containing oligosaccharides, by 
A27V/V163A may be particularly detrimental to colonization because it prevents binding to 
urinary tract surfaces. Thus, in the naive bladder, soluble host proteins and oligosaccharides may 
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act as decoy receptors, whereas in the catheterized bladder, soluble host proteins may aid in 
binding of bacteria to the implant. Together, these studies demonstrate that the preexisting 
conformational ensemble and corresponding mannose affinity of FimH determine the outcome of 
infection. Further, the results suggest that positive selection balances the conformational 
equilibrium of FimH in solution between R and T states to tailor moderate affinity to UPEC for 
the urothelium, thus facilitating adherence to and persistence in the bladder. 
 
Discussion 
Our interdisciplinary studies combining evolutionary biology and computational and 
molecular biophysics allowed us to directly interrogate, at the atomic and structural level, the 
multiple conformations that FimH adopts in solution in a tip-like setting within a two-state, T-
R conformational landscape (Fig. 7A). Positively selected residues influence the preexisting 
conformational equilibrium of the two-domain FimH by shifting the relative occupancies of a 
dynamically restrained T state conformation and multiple R state conformations that sample a 
great expanse of bends, twists, and orientations through ball-and-socket joint-like motions. As a 
result of these population shifts, natural sequence variation alters the apparent affinity of FimH 
toward mannosylated ligands. Thus, the conformational phase space of FimH in solution and 
population shifts spurred by positively selected residues further provide a framework for 
understanding the structural basis of allosteric coupling between interdomain interactions and 
mannose binding. Classically, the mechanism underlying protein allostery has been conceptualized 
as a deterministic process, in which information is transmitted through structural perturbations 
from one site of a protein to another in a sequential or concerted manner [39-41]. However, recent 
synergy in the fields of protein biophysics and protein evolution has given rise to the emerging 
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perspective that protein allostery is a natural and statistical consequence of shifts in the relative 
populations and/or dynamics of preexisting conformational ensembles [42, 43], which is supported 
by this work. Furthermore, by influencing the preexisting equilibrium of FimH, positively selected 
residues alter the very pathway through which binding occurs: If a particular FimH variant favors 
the T state, it will favor an induced-fit mechanism of binding; if a FimH variant favors the R state, 
it will use conformational selection as its mechanism of binding. 
Our structural, biophysical, and computational work indicate that the low-affinity T and 
high-affinity R conformations can bind mannose through distinct binding orientations and 
pathways. Consistent with previous cocrystal structures, simulations of the R state indicate that 
mannose and oligomannose-3 bind in a high-affinity horizontal orientation coordinated through 
hydrogen bond formation with residue F1 and residues in loops 2 and 3 and clamped by residue 
I13 in loop 1. Our simulations and a recent crystal structure of the T state bound to heptyl 
mannoside [26] also indicate that the T state may bind mannose in this horizontal orientation, 
particularly when loop 1 is proximal to the binding pocket. In addition to this binding mode, 
mannose also approaches and binds the T state pocket in a tilted orientation, specifically to residue 
F1 of the N terminus and D54 of loop 2, in a low-affinity interaction. Mannose glycans may slide 
and rotate and interact with the conformationally dynamic tyrosine gate of FimH. This novel ligand 
entry and rotation pathway may represent a stepwise mechanism through which induced-fit 
binding proceeds, whereby interactions in the T state trigger structural perturbations within 
FimHLD that culminate in T-R conformational changes. Furthermore, tight binding of mannose 
through multiple different bends and orientations of the R state, as indicated in our simulations, 
provides the basis for a physical model, here termed molecular tethering, by which bacteria can 
remain bound to their mannosylated receptors on the bladder surface (Fig. 7B). Entropic freedom 
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of multiple bound conformations within the high-affinity R state would theoretically enhance the 
lifetime of mannose binding relative to a single high-affinity R state. Moreover, the enhanced 
conformational flexibility and the number of viable bound R conformations in FimH may increase 
the biophysical adaptability of type 1 pili while tethered to a surface in part to allow attached 
bacteria to resist urine flow while bound to the bladder epithelium [44, 45]. Molecular tethering 
likely represents a universal feature of macromolecular interactions involving Gram-negative 
adhesins or any other two-domain, allosterically regulated protein containing a flexible linker. 
Coupled with genetic and in vivo pathogenesis work, we have demonstrated how 
evolutionary pressures through positive selection in FimH allosterically shape the conformational 
dynamics and phase space of FimH to maintain a balanced conformational equilibrium 
between R and T states to allow UPEC to colonize the urinary tract (Fig. 7C). Surprisingly, a 
FimH variant that only adopts the high-affinity R state is severely attenuated early in a mouse 
model of uncomplicated UTI but is proficient at colonizing catheterized bladders in vivo or bladder 
transitional-like epithelial cells in vitro. Given how early the pathogenesis defect of A27V/V163A 
is observed relative to WT (within 1 hpi), some preset aspect(s) of the bladder habitat likely select 
against the high-affinity R conformation(s). One possibility may relate to the slower kinetics of 
association of the R state under conditions of flow, as part of a catch-bond mechanism [44-46], 
which, in the case of A27V/V163A, would translate to less frequent interactions with the bladder 
epithelium and increased clearance of bacteria from the bladder during periods of urination. A 
second possibility is that some inherent property of the bladder epithelium serves as a restrictive 
factor against the R state. We suggest that the superficial facet cells may mediate this restriction, 
because the A27V/V163A variant is capable of binding 5637 bladder cells in vitro and can mediate 
the colonization of the catheter-implanted bladder habitat. A third possibility is that soluble 
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mannosylated glycoproteins, such as THP, and mannose-containing oligosaccharides [47] may 
serve as decoy receptors that reduce the ability of A27V/V163A to colonize the bladder epithelium 
because it binds more tightly than WT to THP. These same host proteins that serve as decoys in 
host defense may facilitate bacterial colonization by coating the catheter [36, 38]. More work is 
required to dissect the individual and combinatorial contributions that the abovementioned 
possibilities may exert in preventing the high-affinity R state in mediating successful bladder 
colonization. Together, our data suggest that the T state may serve to temporarily mask the strong 
affinity that FimH has for mannose to avoid restrictive factors or properties native to the bladder 
habitat to initiate productive binding when engaging the host epithelium. 
Fundamentally, this encompassing study of solution protein dynamics, structure, and 
function exemplifies the importance of defining the native conformational ensembles of a protein 
in solution and its population shifts in the presence of ligand for a complete model of allosteric 
regulation. Understanding mechanistic and structural aspects of adhesin allostery, conformation, 
and function is critical in efforts to further develop antibiotic-sparing small molecules and vaccines 
for the treatment of acute and recurrent infections caused by UPEC and other pathogens. 
  
Materials and methods 
Ethics statement 
All animal experiments were conducted according to the National Institutes of Health 
(NIH) Guide for the Care and Use of Laboratory Animals and performed in accordance with 
institutional regulations after pertinent review and approval by the Animal Studies Committee at 
Washington University School of Medicine (protocol number 20150226). Human urine collection 
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was performed with informed consent and approved under Institutional Review Board protocol 
201207143. 
FimH variants 
In silico analysis of FimH sequences among 287 E. coli strains previously revealed three 
specific residues (positions 27, 62, and 163) evolving under positive selection. Variations at these 
three positions in the FimH sequence from UPEC strain UTI89 were examined in this study. These 
include the following: (i) the WT variant (A27/A62/V163), in which these three amino acids are 
together observed in E. coli isolates from infected urine (19 of 254 strains) but not in isolates from 
healthy feces (0 of 33 strains); (ii) the A62S variant (A27/S62/V163), in which these three amino 
acids are together observed in high abundance in isolates from both infected urine (169 of 254 
strains) and healthy feces (28 of 33 strains); and (iii) the engineered A27V/V163A variant 
(V27/A62/A163), in which these three amino acids have not been observed in tandem and have 
been shown to negatively affect pathogenesis in vivo. The mannose-binding pocket mutant 
Q133K, which cannot bind mannose, was also incorporated in this study as a negative control. 
These variants were generated by site-directed mutagenesis of the WT FimH allele from UTI89, 
as described in a previous report [13]. 
Protein expression and purification 
FimCH variant complexes were purified from periplasm preparations, as previously 
described [14]. FimGNteH complexes were assembled by a spontaneous in vitro DSE reaction, in 
which FimGNte peptide (FimG residues 1 to 15; EZBiolab) was mixed in ~10× molar excess with 
FimCH variant complexes in 15 mM MES (pH 5.6) and 50 mM NaCl and incubated at 37°C for 
16 hours. FimGNte displaces FimC in this reaction, and resultant FimGNteH variant complexes were 
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purified away from excess FimGNte peptide and free FimC using a SOURCE 15S column (GE) in 
15 mM MES (pH 5.6) with a gradient of 0 to 400 mM NaCl. Pooled fractions containing FimGNteH 
variant complexes were dialyzed against 15 mM MES (pH 5.6) and 50 mM NaCl, concentrated to 
1 to 5 mg/ml, and stored stably at 4°C for use in biophysical assays. 
Mannoside incubations 
Mannoside compound 4Z269 (para-biphenyl-2-methyl-3′-methyl amide mannoside) [27] 
was incubated with FimGNteH variant complexes for at least 1 hour at 4°C before biophysical 
analysis at molar ratios indicated below. 
Differential scanning fluorimetry 
FimGNteH variants (10 μM) in the absence or presence of 4Z269 (10 μM) were combined 
with 5× SYPRO Orange (Sigma; 1:1000 dilution of 5000× stock) in 50 μl of reaction mixture 
buffered in 15 mM MES (pH 5.6), 50 mM NaCl, and 0.4% dimethyl sulfoxide. Binding equilibria 
were established by allowing the reaction mixtures to incubate at 23°C for 30 min. These reaction 
mixtures were then placed in 96-well clear-bottom polymerase chain reaction plates and subjected 
to a melt curve from 20° to 90°C in 0.5°C increments of 15 s, each followed by a fluorescence 
read of the “HEX” channel in a Bio-Rad CFX96 thermocycler. Melt curves were fitted to the 
Boltzmann equation [y = A2 + (A1 − A2)/(1 + exp((x − xo)/dx)), where xo is the Tm] to determine the 
melting temperature (Tm). 
Enzyme-linked immunosorbent assay 
Immulon 4HBX 96-well plates were coated overnight with 1 μg of human glycoproteins 
reported to be ligands of FimH (secretory IgA, laminin, collagen IV, and THP). All glycoproteins 
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were ordered from Sigma except crude THP, which was isolated by ammonium sulfate 
precipitation of urine donated by healthy volunteers. Coated wells were then incubated with 200 
μl of blocking buffer [phosphate-buffered saline (PBS) + 2% bovine serum albumin (BSA)] for 2 
hours at 23°C, followed by incubation with 100 μl of FimGNteH variants diluted in blocking buffer 
to 1 μg/ml for 1 hour at 37°C. After washing three times with PBS + 0.05% Tween 20, 100 μl of 
polyclonal rabbit antibody raised against FimH residues 1 to 165 (from E. coli strain J96) with a 
C-terminal six-histidine tag (Sigma Genesis; 1:5000 dilution in PBS + 2% BSA) was added to 
each well for 1 hour at 37°C. After washing three times with PBS + 0.05% Tween 20, 100 μl of 
polyclonal goat anti-rabbit antibody conjugated to horseradish peroxidase (KPL; 1:5000 dilution 
in PBS + 2% BSA) was added to each well for 1 hour at 37°C. After a final round of washing, 
plates were developed with 100 μl of tetramethylbenzidine substrate (BD Biosciences) and 
quenched within 1 min with 50 μl of 1 M H2SO4, and absorbance was measured at 450 nm. 
Small-angle x-ray scattering 
Before sample submission, FimCH and FimGNteH variant complexes were buffer-
exchanged three to five times in Spin-X UF 5K concentrators (Corning) against freshly prepared 
buffer [15 mM MES (pH 5.6) and 50 mM NaCl] to a final concentration of 5 to 8 mg/ml. 
FimGNteH:4Z269 complexes were prepared in the same manner after FimGNteH variants were 
incubated with 4Z269 at a 1:2 molar ratio. Samples were diluted to 1 to 5 mg/ml using the final 
filtrate to ensure identical buffer conditions between buffer and sample. Samples were then 
shipped to the SIBYLS beamline at the Advanced Light Source for data collection and basic data 
processing, including scattering integration and buffer subtraction, as detailed extensively in the 
high-throughput mail-in SAXS protocol [48]. Integrated scattering profiles were then inspected 
and analyzed using the ATSAS program suite [49]. At least 9 to 12 scattering profiles representing 
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multiple concentrations and exposures were merged in PRIMUS to generate an average scattering 
profile for each sample tested. Pair distance distributions [p(r)] and maximal intramolecular 
distances (Dmax) were determined by GNOM. Structural comparison maps were calculated, as 
previously described, using the SIBYLS SAXS Similarity online tool 
(http://sibyls.als.lbl.gov/saxs_similarity/) [50]. Fits of crystal structures to merged scattering 
profiles were evaluated by the FoXS and MultiFoXS servers in the case of single-state and 
multistate rigid-body modeling, respectively. For each sample, 10 ab initio models were generated 
through simulated annealing by GASBOR [51] and averaged by DAMAVER [52]. The resultant 
low-resolution molecular envelope of each sample was represented in PyMOL by setting the van 
der Waals distance (vdw) to 5.0 Å and the solvent radius (solvent_radius) to 4.5 Å. 
Native electrospray ionization and IMMS 
FimGNteH variant complexes in 15 mM MES (pH 5.6) and 50 mM NaCl were diluted to 10 
to 20 μM protein concentration and underwent multiple rounds of buffer exchange through dilution 
and concentration into 100 mM ammonium acetate (pH 6.5) (>99.99% trace metals basis) such 
that the final salt concentration was reduced to lower than 10 to 20 μM for clean native electrospray 
ionization (nESI) spectra. FimGNteH:4Z269 complexes were prepared in the same manner after 
FimGNteH variants were incubated with 4Z269 at a 1:1 molar ratio. Samples were loaded at 5 to 
10 μl in custom-made electrospray capillaries and injected into a hybrid ion mobility quadrupole 
time-of-flight mass spectrometer (SYNAPT G2 High Definition Mass Spectrometry, Waters). The 
instrument was operated under gentle ESI conditions (capillary voltage, 1.5 to 2.2 kV; sampling 
cone, 2 V; extraction cone, 1 V; source temperature, 36°C). CE was varied to observe dissociation 
events between FimGNte, FimH, and 4Z269. The pressure of the vacuum/backing region was 5.1 
to 5.6 mbar. For the ion mobility measurements, the helium gas flow to the collision cell was 70 
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ml/min, the ion-mobility spectrometry (IMS) gas flow was 35 ml/min, the IMS wave velocity was 
500 m/s, and the IMS wave height was 20 V. Nitrogen was used as the mobility carrier gas. The 
instrument was externally calibrated up to 8000 mass/charge ratio (m/z) with the clusters produced 
by ESI of NaI solution (100 mg/ml). The peak picking and data processing were achieved by using 
MassLynx (version 4.1) and DriftScope software (Waters). The CCSs for protein ions were 
converted using previously published calibration protocols and databases [53]. FimGNteH variants 
in the presence or absence of 4Z269 were aerosolized by nESI, and native mass spectra were 
acquired under a range of CEs (5 to 40 V). Each spectrum was acquired every 1 s for 2 min and 
gated at m/z values of 3054 to 3056 (apo) and 3094 to 3096 (+4Z269) for the +10 charge state. 
These spectra indicated that all FimH variants entered the gas phase as an intact FimGNteH complex 
at low CE but steadily dissociated with increasing CE (fig. S3A). These spectra also revealed that 
FimGNteH variants stably associated with 4Z269 in accordance with the relative binding strengths 
of the FimH alleles: 4Z269 occupies ~100% of A27V/V163A, ~90% of WT, ~50% of A62S, and 
~0% of Q133K (fig. S3B). The +10 charge state corresponding to intact FimGNteH variants was 
then subjected to ion mobility analysis at various CEs. CCS distributions were modeled as a sum 
of two Gaussian curves because modeling by one Gaussian curve resulted in significantly poorer 
fits in nearly all cases (table S2). 
Protein crystallization and structure determination 
Crystals of FimGNteH A62S grew under numerous polyethylene glycol (PEG) conditions 
at 20°C by hanging drop vapor diffusion in 96-well plates. The diffracted crystals of FimGNteH 
A62S were grown within the PEG II crystallization screen (Qiagen) by mixing 100 nl of protein 
(7.5 mg/ml) with 100 nl of mother liquor [0.2 M calcium acetate, 0.1 M Hepes (pH 7.5), and 10% 
PEG 8000] and equilibrated against 75 μl of mother liquor in the reservoir. These crystals took on 
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a thick rectangular prism morphology and were picked directly from the 96-well screen. They were 
transferred into a cryoprotectant [0.2 M calcium acetate, 0.1 M MES (pH 5.6), 25% PEG 8000, 
and 20% glycerol] and then flash-frozen in a cryostream. Crystals of FimGNteH A27V/V163A 
were grown at 20°C by hanging drop vapor diffusion by mixing 1 μl of protein (5 mg/ml) with 1 
μl of mother liquor [0.2 M calcium acetate, 0.1 M Hepes (pH 7.5), and 5% PEG 8000] and 0.5 μl 
of 0.1 M cadmium chloride and equilibrated against 1 ml of mother liquor in wells of a 24-well 
plate. These crystals took on a thin-plate morphology. They were transferred into a cryoprotectant 
[0.2 M calcium acetate, 0.1 M Hepes (pH 7.5), 25% PEG 8000, and 20% glycerol] and then flash-
frozen in a cryostream. Diffraction data were collected at 100 K at an in-house facility equipped 
with a rotating anode (Rigaku MicroMax-007 generator), a Rayonix marmux x-ray source, and a 
Mar345 image plate detector. Data were indexed and integrated in iMosflm [54] and scaled by 
Scala [55]. The phase problem was solved by MR using Phaser-MR in Phenix [56] with two 
distinct search ensembles: (i) FimHPD (from PDB ID 1KLF) and FimHLD in the T state (from PDB 
ID 3JWN) as separate domains and (ii) FimHPD (from PDB ID 1KLF) and FimHLD in the R state 
(from PDB ID 1KLF) as separate domains. The best solutions were identified as a T conformation 
for FimGNteH A62S and a bent R conformation (90° between FimHLD and FimHPD) for FimGNteH 
A27V/V163A. Several rounds of refinements were performed in phenix.refine to improve the final 
models. 
Molecular dynamics 
Crystal structures of FimGNteH published in this study along with models of FimGNteH 
based on previous crystal structures (GNte docked on H from CH structure) in the absence or 
presence of ligands were used to initiate MD simulations. Structural models of FimGNteH variants 
were created with the in silico mutagenesis wizard in PyMOL after the mutant side-chain rotamer 
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with the fewest steric clashes was selected. Structural models were then prepared within the 
CHARMM36 force field and the TIP3P water model by the MD software package GROMACS-
4.6.7 [57]. The system was first solvated in a cubic box, with sides equal to 130 Å in the presence 
of 50 mM NaCl. The structure was then energy-minimized to reduce steric clashes, and the system 
was finally equilibrated at constant temperature (37°C) and pressure (1 atm). Conventional 
unrestrained MD simulations were then performed with steps of 2 fs for a total time of ~15 to 20 
ns for each run, collecting four replicates for simulations on the T (5JQI), bent R (5JR4), 
and elongated R (based on 1KLF) conformations for WT FimH. Longer simulations were also 
performed at 100 to 200 ns for three replicates for all FimH variants in these conformations with 
similar results. Coordinates were saved every 0.1 ns. Commands in GROMACS and graphical 
output in MATLAB were used to analyze simulation trajectories. 
Conformational phase space 
Conformational phase space calculations were performed with custom in-house scripts in 
PyMOL and MATLAB after alignment of the pilin domain to a reference structure (FimHPD from 
FimCH). The coordinates of the following atoms were tracked and assigned the corresponding 
labels: Leu225 and CD2 (pip1 for “point in pilin 1”), Leu193 and CD1 (pip2), Ala247 and N 
(pip3), Leu193 and CA (pip4), Leu129 and CD2 (pil1 for “point in lectin 1”), Val20 and CG1 
(pil2), and Val105 and N (pil3). The points {pip1, pip2} and {pip2, pil1} define vectors along the 
longest dimension of FimHPD and FimHLD, respectively. The points {pip2, pip3, pip4} and {pil1, 
pil2, pil3} define transverse planes that respectively bisect FimHPD and FimHLD perpendicular to 
the axis of the longest dimension. Bend angle is defined as the {pip1, pip2, pil1} angle. Twist 
angle is defined as the {pip1, pip2, x} angle, where x is defined as the point on the {pil1, pil2, pil3} 
plane at a fixed radial distance from pil1 that is closest to the {pip2, pip3, pip4} plane. Orientation 
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angle is defined as the {pip3, pip2, y} angle, where y is the point on the {pip2, pip3, pip4} plane 
closest to x. These angles are schematically represented in fig. S5A. 
Mouse infections 
For the uncomplicated UTI model, 7- to 8-week-old female C3H/HeN mice were obtained 
from Envigo. Mice were anesthetized and inoculated via transurethral catheterization with 50 μl 
of bacterial suspension (~1 × 107 to 2 × 107 CFU in total) in PBS. At times indicated, mice were 
sacrificed, and bladders were aseptically removed and processed for CFU determination [37]. For 
the CAUTI model, a 5-mm piece of silicon tubing (RenaSil 0.635-mm outer diameter) was inserted 
transurethrally into the bladders of 6-week-old female C57BL/6 mice, as previously described 
[37]. Twenty-four hours after implantation, the mice were transurethrally infected with ~2 × 
107 CFU of UTI89 expressing either the WT or A27V/V163A allele of FimH with the fim operon 
locked in the phase on state [13]. Mice were sacrificed 24 or 72 hpi, and bacteria colonizing the 
bladder and implant were plated for quantification. 
Bladder epithelial cell studies 
Human bladder epithelial cells, designated 5637 (ATCC HTB-9) cells, were obtained from 
the American Type Culture Collection and maintained in RPMI 1640 supplemented with heat-
inactivated 10% (v/v) fetal bovine serum at 37°C in the presence of 5% CO2. Confluent, serum-
starved 5637 cells in 24-well plates were infected with UTI89 strains at a multiplicity of infection 
of 10. After 30 min, culture media were replaced either by fresh culture media or by media with 
gentamicin sulfate (120 μg/ml) (Sigma-Aldrich) to kill extracellular bacteria. Cells were further 
incubated for 1 hour, washed rigorously, solubilized with 1% Triton X-100, quenched with PBS, 
and plated for bacterial CFU quantification. 
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Figure 1. Structure-function relationship in the type 1 adhesin FimH. (A) Schematic 
representation of FimH sequence. The lectin domain (FimHLD, residues 1 to 155) is colored blue, 
the linker is colored yellow (residues 156 to 160), and the pilin domain (FimHPD, residues 161 to 
279) is colored teal. (B) Comparison of previously identified conformations of FimH. FimH bound 
to FimC in a FimCH complex exists in a high-affinity conformer, or R state, with an elongated 
orientation between FimHLD and FimHPD, a narrowly packed β-sandwich fold in FimHLD (as 
highlighted between the two black triangles), and packed mannose-binding loops (labeled as L1, 
L2, and L3). FimH in a tip assembly (FimCFFGH complex) adopts a low-affinity conformer, 
or T state, with a compacted orientation between FimHLD and FimHPD, a widened β-sandwich fold 
in FimHLD (as highlighted between the two black triangles), and displaced binding loops 
(particularly L1). Positively selected residues are indicated as red spheres, and the mannose-
binding pocket is shaded gray. (C) Schematic representation of the negatively coupled allosteric 
relationship between mannose and the interface between FimH domains, whereby increases in 
mannose binding disfavor contacts between FimHLD and FimHPD and vice versa. 
 68 
 
Figure 2. Crystal structures and mannose binding of FimH variants in a tip-like setting. (A) 
Reaction scheme of in vitro DSE reaction to produce tip-like FimGNteH complexes. (B) 
Representative SDS–polyacrylamide gel electrophoresis of purified FimGNteH variants either 
boiled (not labeled) or not boiled (NB). (C) Enzyme-linked immunosorbent assay (ELISA) 
measuring binding of FimGNteH variant complexes to surface-coated glycoproteins, which include 
secretory IgA (sIgA), Tamm-Horsfall protein (THP), collagen IV, and laminin. (D) Crystal 
structures of FimGNteH A62S [Protein Data Bank (PDB) ID 5JQI, left] and FimGNteH A27V/V163A 
(PDB ID 5JR4, right) depicted as ribbons. These structures are overlaid on previously solved 
crystal structures of FimH in a FimCFFGH complex (3JWN) and FimCH complex (1KLF), 
respectively. Conformations are labeled accordingly. FimHLD, linker, and FimHPD are colored as in 
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(A), the insertion loop (residues 109 to 124) is colored purple, and FimGNte is colored gray. (E) 
FimHLD-FimHPD interface in FimGNteH A62S (left) and FimGNteH A27V/V163A (right). Contacts 
between residues are indicated as black dotted lines. (F) Structural alignment of FimGNteH 
A27V/V163A (colored blue) to FimHLD of mannose-bound FimCH (colored white). Residue side 
chains and mannose in green are depicted as sticks. Contacts between mannose and FimH are 




















Figure 3. Conformational ensembles of apo and ligated FimH variants in solution. (A) 
Structural comparison heat map of SAXS profiles indicates varying degrees of conformational 
similarity among FimGNteH variants, as measured by χ2, ranging from high (blue) to low (red) 
similarity. (B) Normalized pair distance distributions of FimGNteH variants in the absence or 
presence of 4Z269. FimGNteH variants are represented as solid lines in the absence of 4Z269 or 
dotted lines in the presence of 4Z269 and color-coded, as indicated by the colored lines in (A). (C) 
Structural comparison heat map indicates varying degrees of conformational similarity of each 
FimGNteH variant in the absence or presence of mannoside 4Z269 at a 2× molar ratio. Color-coded 
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as in (A). (D) Averaged ab initio models of FimGNteH variants in the absence or presence of 4Z269 
























Figure 4. Conformational distributions of free and 4Z269-bound FimGNteH variants isolated 
in the gas phase, as revealed by IMMS. (A) CCS distributions of intact FimGNteH variant 
complexes measured by IMMS. (B) Comparison of CCS distributions of free (solid line) and 
4Z269-bound (dotted line) FimGNteH variants. The solid and dotted black lines represent fitted 
Gaussian distributions to apo and ligated FimGNteH, respectively. Fitted Gaussian distributions are 
labeled by letters, given their mean CCS values. Note that Q133K cannot bind mannose and that 
the dotted lines for this variant represent CCS distributions and Gaussian fits to an independently 










Figure 5. Dynamics and binding mechanisms of conformational populations in FimGNteH 
WT. (A) Structures revealed by MD simulations of FimGNteH WT in a T conformation (top) 
or bent R conformation (bottom) with corresponding measures of structural fluctuation over time 
(RMSD) and distributions of sampled protein shapes (Rg). Different colors correspond to four 
independent simulation replicates. (B) Three-dimensional conformational phase space of 
FimGNteH as defined by bend, twist, and orientation angles for simulations initiated from 
the T (green), bent R (blue), or elongated R (cyan) conformation. Shadows are cast on the grid 
panels and colored in gray. (C) Structures revealed by MD simulations of FimGNteH WT in 
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a T conformation (top) or bent R conformation (bottom) in the presence of mannose, with 
corresponding measures of structural fluctuation over time (RMSD), distributions of sampled 
protein shapes (Rg), and mannose binding. “On” and “Off” measure whether the center of mass of 
mannose is within or outside 10 Å of the carbonyl of residue F1 in the binding pocket. (D) 
Representative binding modes of mannose for T (top) and bent R (bottom) after 5 ns. Mannose is 
depicted as sticks, whereas FimH is shown as a ribbon representation. (E) Structures revealed by 
MD simulations of FimGNteH WT in a T (top) or bent R (bottom) conformation in the presence of 
oligomannose-3 (Man(α1–3)-[Man(α1–6)]-Man), with corresponding measures of structural 
fluctuation over time (RMSD), distributions of sampled protein shapes (Rg), and mannose binding. 
“On” and “Off” measure whether the center of mass of oligomannose-3 is within or outside 20 Å 
of the carbonyl of residue F1 in the binding pocket. (F) Representative binding modes of 
oligomannose-3 for T (top) and bent R (bottom) after 8.5 ns. Man(α1–3)-[Man(α1–6)]-Man is 












Figure 6. Role of FimH conformation in bladder colonization during UTI. (A) Bacterial titers 
of mouse bladders infected with UTI89 harboring either FimH WT (blue) or A27V/V163A 
(orange) at an inoculum of 107colony-forming units (CFU) measured at 1, 3, and 6 hpi. (B) Total 
bacterial titers of 5637 bladder epithelial cells (no gentamicin treatment) infected with UTI89 
harboring WT (blue), Q133K (red), A62S (green), or A27V/V163A (orange) FimH at an inoculum 
of 107 CFU. (C) Invaded bacterial titers of 5637 bladder epithelial cells (treated with gentamicin) 
infected with UTI89 harboring WT (blue), Q133K (red), A62S (green), or A27V/V163A (orange) 
FimH at an inoculum of 107 CFU. LOD, limit of detection. (D and E) Bacterial titers of C57BL/6 
mouse bladders without catheterization or bladders and implants infected with UTI89 harboring 
either FimH WT (blue) or A27V/V163A (orange) at an inoculum of 107 CFU 24 hours after 
catheterization. **P < 0.01, ***P < 0.001, ****P < 0.0001, two-tailed Mann-Whitney U test. 
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Figure 7. Proposed model of FimH conformational ensembles, mannose binding, and 
virulence in UTI. (A) Two-state conformational landscape of FimH. FimH at the pilus tip natively 
adopts an equilibrium of a single, dynamically restrained, low-affinity T state and multiple, highly 
dynamic, high-affinity R states with various bends, twists, and orientations. Positively selected 
residues can shift this preexisting conformational equilibrium and thereby influence mannose-
binding affinity. The T and R states can bind mannose. Mannose in a tilted orientation rapidly 
enters into the widened and shallow binding pocket of the T state. Mannosylated ligands in a 
bound T state can then rotate in a high-affinity orientation and allosterically trigger structural 
perturbations that disrupt FimHLD and FimHPDinteractions and facilitate conversion to the 
bound R state. In addition, mannose in a horizontal orientation can less rapidly engage the R state 
but does so very tightly through hydrogen bond interactions with several binding loop residues. 
Positive selection, in modulating a native conformational equilibrium, likely alters flux through 
these two distinct binding mechanisms. (B) Schematic model of the FimH molecular tether. The 
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bends, twists, and orientations between FimHLD and FimHPD adopted in bound R states argue for a 
model in which the pilus tip can bend and rotate at the site of the FimH linker with an immobilized, 
bound FimHLD. This physical tethering in theory increases the biophysical and functional 
adaptability of the pilus and thereby allows bacteria to remain attached to the bladder epithelium. 
(C) Pathogenesis outcomes depend on the preexisting equilibrium and affinity of FimH, whereby 
moderate affinity is ideal for successful colonization of the bladder epithelium and formation of 
IBCs. Catheterization allows the high-affinity variant A27V/V163A to partially circumvent the 



















Figure S1. Structural analysis of solved FimGNteH complex crystal structures. (A) FimGNteH 
A62S (PDB ID 5JQI) crystallizes with four subunits in the unit cell. FimHLD is represented as 
tubes, FimHPD is represented as thin ribbons, and FimGNte is represented as orange tubes. (B) 2Fo-
Fc maps of FimGNteH A62S contoured at 1σ reveal well-resolved electron density for L2 and L3 
but moderate to weak electron density for L1 in chains B, F, and H, likely indicative of a high 
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degree of conformational flexibility in L1 in the crystal. (C) Crystal packing of FimGNteH 
A27V/V163A (PDB ID 5JR4) with symmetry partners colored in gray. (D) Close up of the packing 
interface reveals a calcium ion (green sphere) coordinated by D2 of FimGNte, waters (red spheres), 
and residues G159 and D162 from a neighboring FimH symmetry partner. Calcium acetate was 





















Figure S2. Structural comparison of all known FimH conformations. To date, four truly 
distinct conformational shapes (T, bent R, a distinct bent R, and elongated R) of FimH have been 
elucidated using X-ray crystallography under various conditions and with different binding 
partners, as indicated below each structural model, and with different FimH sequences, as 
indicated in parentheses. These four distinct conformational shapes reflect only two 
conformational states, given the structural homology and mannose binding propensity of the two 







Figure S3. Solution analysis of FimCH and FimGNteH variants. (A) Structural comparison heat 
map of SAXS profiles indicates high degree of conformational similarity among FimCH variants 
as measured by χ2, ranging from high (blue) to low (red) similarity. (B) Normalized pair distance 
distributions of FimCH, color-coded as indicated by the colored lines in (A). (C) Rigid body 
modeling of the FimCH crystal structure (1KLF) to the scattering profiles of FimCH variants 
indicates excellent agreement between crystallographic and solution conformations for all variants. 
(D) Rigid body modeling of four structural models (1: 5JQI=“T”; 2: 5JR4= “bent R”; 3: derived 
from 4XOB = “bent R2”; 4: derived from 1KLF = “elongated R”) to scattering profiles of 
FimGNteH variants in the absence or presence of 4Z269 results in varying goodness of fit. (E) Best-
fitting multi-state models of FimGNteH scattering data. The fitted conformations are colored black 
for T, purple for bent R, yellow for a distinct, previously identified bent R, and cyan for elongated 
R. The relative abundances of these conformations are depicted as weighted percentages, with the 
corresponding goodness of fit shown above each bar. (F) Derivative melting curves obtained by 
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differential scanning fluorimetry (DSF) reveal distinct numbers of and positions in melting 
























Figure S4. Native and ion mobility mass spectra of FimGNteH variants in the absence or 
presence of 4Z269. (A) Native mass spectra of FimGNteH variants in the absence (top) or presence 
(bottom) of 4Z269 at various collision energies are shown, with an increase in free FimGNte and 
decrease in intact FimGNteH complex as CE increases. (B) Comparison of native mass spectra of 
FimGNteH variants in the absence (red) or presence (black) of 4Z269. (C) CCS distributions of 










Figure S5. Conformational dynamics and binding mechanisms of FimGNteH WT. (A) 
Schematic representation of the angles measured to define conformational phase space of FimH. 
(B) Structural alignment of oligomannose-3-chitobiose (Man(α1-3)-[Man(α1-6)]-Man(β1- 4)-
GlcNAc(β1-4)-GlcNAc) to the “horizontal” and “tilted” mannose orientations observed in the 
bound T and R states (“tilted” orientation shown at t=8.5 ns for T state in upper right quadrant; 
“horizontal” orientation shown in all other quadrants). Comparison to the crystal structure of 
FimHLD bound to this high-mannose epitope suggests a mechanism by which mannose may slide 
and rotate and press against the “tyrosine gate” (Y48, Y137) in a high-affinity orientation. Man(α1-
3)-[Man(α1-6)]-Man is depicted as sticks and colored green, yellow, and cyan, respectively, while 
the chitobiose component (GlcNac(β1-4)- GlcNac) is represented as pink sticks. (C) Comparison 
of the distributions of interatomic distances (indicated in graph title) among apo T (n=406), bound 
T (n=293), apo R (n=10), and bound R (n=687) states from simulations in which mannose was 
present. Movement of loop 1 toward the binding pocket is most strikingly associated with mannose 
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binding in the R state but marginally so in the T state. Despite the occasional displacement of loop 
1 away from the R pocket, mannose can remain stably associated with R. Loop 3 is consistently 
more proximal to the pocket in the R state over the T state, contributing to high-affinity 
interactions. In addition, pocket width (defined as the distance between the two residues F1 and 
D54 which coordinate the C6 hydroxyl group of mannose) is larger by 2 Å in the R state and thus 
more capable of forming stronger hydrogen bonds with mannose compared to the T state. 
Furthermore, residue Q133 is generally further away from the binding pocket in the T state than 
in the R state due to structural difference in T and R pockets, but when Q133 does move closer to 
the center of the pocket in the T state, it tends to disfavor mannose binding. Thus, the Q133K 
mutation abolishes mannose binding through steric hindrance of mannose entry in either the T or 
R pockets. Statistical significance was determined by the non-parametric Mann-Whitney U test, 
where *** indicates p<0.005 and **** indicates p<0.0001. (D) Melting temperatures observed by 






















Table S1. Data collection and refinement statistics 
 
 FimGNteH A62S (5JQI) FimGNteH A27V/V163A 
(5JR4) 
Data collection   
Space group P1 C2 
Cell dimensions     
    a, b, c (Å) 56.4, 75.6, 78.4 122.3, 33.0, 72.5 
  α, β, γ (°)  68.4, 69.0, 77.4 90.0, 120.6, 90.0 
Resolution (Å) 49.8-1.96 (2.03-1.96) * 62.4-2.60 (2.73-2.60) * 
Rmerge (%)a 14.1 (70.6) 16.4 (48.2) 
Rpim (%)b 2.4 (41.8) 3.8 (21.2) 
I / σI 8.5 (1.6) 8.1 (3.3) 
Completeness (%) 83.4 (90.4) 99.6 (95.1) 
Multiplicity 3.9 (3.8) 6.4 (6.0) 
CC1/2 0.99 (0.85) 1.0 (0.68) 
Total / Unique reflections 297,496 / 75,411(40,054 / 
10,548) 
51,190 / 7,964 (6,606 / 1,106) 
 
Refinement   
Rworkc/ Rfreed 20.1 / 24.7  21.4 / 26.5 
No. atoms   
    Protein 8,522 2,138 
    Ligand/ion 24 7 
    Water 890 24 
B-factors   
    Protein 23.0 31.9 
    Ligand/ion 27.9 34.8 
    Water 27.3 30.9 
R.m.s. deviations   
    Bond lengths (Å) 0.004 0.012 
    Bond angles (°) 
Ramachandran plot 
    favored (%) 
    allowed (%) 
















aRmerge = Σhkl Σi |Ii(hkl)-<I(hkl)>|/Σhkl ΣiIi(hkl), where the sum i is over all separate 
measurements of the unique reflection hkl. 
bRpim =  Σhkl [1/(n-1)]1/2 Σi|Ii(hkl)–<I(hkl) >|/Σhkl Σi Ii(hkl) 
bRwork = Σhkl ||Fobs| - |Fcalc||/ Σhkl |Fobs| 
cRfree, calculated the same as for Rwork but on the 5% data randomly excluded from the refinement 
calculation. 
*the outer resolution shell. Values in parentheses indicate the highest resolution shell 
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a All CCS distributions were fit by either one Gaussian or a sum of two Gaussian peaks. The best 
fits are presented in this table. Two Gaussians explained the data better than one Gaussian, 
increasing R2 by 5% and improving the residual plots in all cases except for A27V/V163A + 







































0.9985 60 40 --- 
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 Treatment of bacterial infections is becoming a serious clinical challenge due to the global 
dissemination of multidrug antibiotic resistance, necessitating the search for alternative treatments 
to disarm the virulence mechanisms underlying these infections. Uropathogenic Escherichia coli 
(UPEC) employs multiple chaperone–usher pathway pili tipped with adhesins with diverse 
receptor specificities to colonize various host tissues and habitats. For example, UPEC F9 pili 
specifically bind galactose or N-acetylgalactosamine epitopes on the kidney and inflamed bladder. 
Using X-ray structure-guided methods, virtual screening, and multiplex ELISA arrays, we 
rationally designed aryl galactosides and N-acetylgalactosaminosides that inhibit the F9 pilus 
adhesin FmlH. The lead compound, 29β-NAc, is a biphenyl N-acetyl-β-galactosaminoside with a 
Ki of ∼90 nM, representing a major advancement in potency relative to the characteristically weak 
nature of most carbohydrate–lectin interactions. 29β-NAc binds tightly to FmlH by engaging the 
residues Y46 through edge-to-face π-stacking with its A-phenyl ring, R142 in a salt-bridge 
interaction with its carboxylate group, and K132 through water-mediated hydrogen bonding with 
its N-acetyl group. Administration of 29β-NAc in a mouse urinary tract infection (UTI) model 
significantly reduced bladder and kidney bacterial burdens, and coadministration of 29β-NAc and 
mannoside 4Z269, which targets the type 1 pilus adhesin FimH, resulted in greater elimination of 
bacteria from the urinary tract than either compound alone. Moreover, FmlH specifically binds 
healthy human kidney tissue in a 29β-NAc–inhibitable manner, suggesting a key role for F9 pili 
in human kidney colonization. Thus, these glycoside antagonists of FmlH represent a rational 






Urinary tract infections (UTIs) are one of the most prevalent infections, afflicting 15 
million women per year in the United States alone, with annual healthcare costs exceeding $2 to 
$3 billion [1-3]. Nearly 50% of women will experience at least one UTI in their lifetime. Despite 
appropriate and often successful clearance of bacteriuria by antibiotic treatment, 20% to 30% of 
women will experience a recurrence within 6 mo of the initial acute UTI [1, 4]. Kidney infection, 
or pyelonephritis, represents a severe manifestation of UTI, with ∼250,000 cases and 100,000 
hospitalizations per year in the United States [5]. Acute pyelonephritis requires hospital admission 
and i.v. antibiotics to thwart the long-term sequelae of kidney failure and renal scarring, and, 
together with bacteremia, results in a mortality rate of 10% to 20% [6–8]. With the global 
dissemination and increase of antibiotic resistance, treatment of UTI is becoming a serious clinical 
challenge [9]. Antibiotic susceptibility tests indicate that many uropathogens are resistant to 
traditional first-line antibiotics like trimethoprim-sulfamethoxazole (TMP-SMZ) and even to last-
line antibiotics such as ciprofloxacin and colistin [10-15]. The diminishing efficacy of antibiotic 
therapies toward UTIs and other infectious diseases demands alternative antibiotic-sparing 
approaches to combat bacterial pathogens. Recently, promising efforts have been made to target 
the virulence mechanisms that cause bacterial infection. These studies have provided much-needed 
therapeutic alternatives, which simultaneously reduce the burden of antibiotic resistance and 
minimize disruption of gastrointestinal microbial communities that are beneficial to human health 
[16]. 
Uropathogenic Escherichia coli (UPEC) is the main etiological agent of UTIs, accounting 
for greater than 80% of community-acquired UTIs [17, 18]. Comparative genomic studies have 
revealed that UPEC strains are remarkably diverse, such that only 60% of the genome is shared 
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among all strains [19]. As a consequence, UTI risk and outcome are determined by complex 
interactions between host susceptibility and diverse bacterial urovirulence potentials, which can 
be driven by differences in the expression and regulation of conserved functions. The ability of 
UPEC to colonize various habitats, such as the gut, kidney, and bladder, depends in large part on 
the repertoire of adhesins encoded in their genome. The most common mechanism for adhesion 
utilized by UPEC is mediated through the chaperone–usher pathway (CUP), which generates 
extracellular fibers termed pili that can confer bacterial adhesion to host and environmental 
surfaces, facilitate invasion into host tissues, and promote interaction with other bacteria to form 
biofilms [20]. Phylogenetic analysis of Escherichia genomes and plasmids predicts at least 38 
distinct CUP pilus types, with single organisms capable of maintaining as many as 16 distinct CUP 
operons [21]. Many of these CUP pilus operons contain two-domain, tip-localized adhesins, each 
of which likely recognize specific ligands or receptors to mediate colonization of a host and/or 
environmental niche. For example, the type 1 pilus adhesin FimH binds mannosylated 
glycoproteins on the surface of the bladder epithelium, which is crucial for the establishment of 
cystitis [22, 23]. The structural basis of mannose (Man) recognition by the N-terminal–receptor 
binding domain, or lectin domain (LD), of FimH has been leveraged to rationally develop high-
affinity aryl mannosides [24-32]. In mouse models of UTI, we have previously demonstrated that 
orally bioavailable mannosides that tightly bind FimH can prevent acute UTI, treat chronic UTI, 
and potentiate the efficacy of existing antibiotic treatments like TMP-SMZ, even against 
antibiotic-resistant E. coli strains [28]. Thus, use of mannosides that target the adhesin FimH 
represents the first successful application of an antivirulence strategy in the treatment of UTI. 
A homolog of the type 1 pilus, the F9 pilus, is one of the most common CUP pili in the E. 
coli pan genome and an important urovirulence factor employed by UPEC for the maintenance of 
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UTI [21, 33]. Our recent work has demonstrated that UPEC up-regulates the expression of F9 pili 
in response to bladder inflammation and epithelial remodeling induced upon UPEC infection [34]. 
These pili display the FimH-like adhesin FmlH, which is capable of binding terminal galactose 
(Gal), N-acetylgalactosamine (GalNAc), or Thomsen-Friedenreich antigen (TF) [Gal(β1-
3)GalNAc(α)]. FmlH was shown to bind TF within naïve or infected kidneys and to Thomsen 
nouvelle antigen (Tn) (GalNAc) within the inflamed bladder epithelium during chronic, 
unresolved UTI. Deletion of FmlH in the urosepsis isolate CFT073 resulted in a competitive defect 
in the ability of this strain to maintain murine UTI in C3H/HeN female mice. Furthermore, 
vaccination with the LD of FmlH (FmlHLD) as the challenge antigen significantly protected mice 
from developing UTI. Thus, we have shown that FmlH serves a key role in the UPEC pathogenesis 
cascade and represents a promising target for antivirulence therapies for UTI in both the bladder 
and kidney habitats. 
Herein, we describe the discovery and structure-based optimization of high-affinity aryl 
galactoside and N-acetylgalactosaminoside FmlH ligands that potently inhibit the function of 
FmlH. Treatment with these FmlH antagonists significantly reduced bacterial burdens in the 
kidneys and bladders of infected mice, thereby demonstrating promising translational value in the 
treatment of UTI in humans. The results of these studies, together with our previous work on FimH 
mannosides, further support the mechanistic and therapeutic value of antivirulence strategies that 
leverage structure-function relationships of diverse bacterial adhesins for the rational design of 
high-affinity glycosides for the treatment of UTI and other bacterial infections. 
 
Results 
O-nitrophenyl β-Galactoside Identified as Early Lead Inhibitor of the F9 Pilus Adhesin FmlH  
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 We revealed in a previous communication that FmlH binds surface glycan receptors 
containing terminal Gal, GalNAc, or TF residues [34]. Given the role of FmlH in UTI 
pathogenesis, we aimed to develop high-affinity galactoside antagonists of FmlH through an X-
ray structure-guided medicinal chemistry approach. This strategy entailed (i) screening a select 
library of galactosides through multiplex ELISA arrays for initial lead compound identification; 
(ii) an iterative process of cocrystal structure determination, virtual screening, structure-based 
ligand design, and in vitro biochemical characterization; and (iii) evaluation of the top lead 
compound in a mouse model of UTI (Fig. 1A). Toward these goals, we first investigated whether 
Gal, GalNAc, and TF could be adapted to function as soluble, competitive inhibitors of FmlH. To 
that end, an ELISA-based competition assay was developed to detect binding of FmlHLD to 
surface-immobilized desialylated bovine submaxillary mucin (ds-BSM) in the presence or absence 
of soluble compounds (Fig. 1A). As expected, Gal, GalNAc, and TF were each capable of 
inhibiting FmlHLD at a concentration of 1 mM, with GalNAc exerting greater inhibitory potency 
than TF or Gal. However, neither Man nor glucose (Glc) had any detectable effect on the ability 
of FmlHLD to bind ds-BSM (Fig. 1B). Lactose (Lac), or Gal(β1-4)Glc, was also incapable of 
inhibiting FmlHLD, demonstrating the high selectivity in which FmlHLD engages Gal-containing 
glycans (Fig. 1B). O-nitrophenyl β-galactoside (ONPG) and isopropyl β-thiogalactoside (IPTG) 
were also tested for inhibition in this exploratory phase of our search for FmlH inhibitors. While 
IPTG exerted minor inhibitory activity at 100 μM, ONPG was found to block FmlHLD from 
interacting with ds-BSM more effectively than Gal, GalNAc, or TF (Fig. 1B). The strong 
inhibitory potency of ONPG suggested that β-galactosides could potentially be rationally designed 
with higher affinity by specifically targeting residues within and surrounding the sugar binding 
pocket of FmlH. 
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 Therefore, X-ray crystallography was implemented to elucidate the 3D structures of both 
apo and ligand-bound FmlHLD (SI Appendix, Table S1). First, a crystal structure of apo FmlHLD 
was solved at 1.6 Å resolution by molecular replacement using FimHLD [Protein Data Bank (PDB) 
ID 3MCY] as the search model. Within this structure, two copies of FmlHLD are found in the 
asymmetric unit, each of which adopts a canonical β-sandwich fold, with three distinct binding 
loops (loop 1: residues 10 to 15; loop 2: residues 44 to 53; and loop 3: residues 132 to 142) that 
form a wide, shallow, solvent-exposed binding pocket (Fig. 1 C and D). Within the binding pocket 
of both copies resides a sulfate ion, which interacts with residues implicated in Gal binding (Fig. 
1D). Cocrystal structures of FmlHLD bound to TF and of FmlHLD bound to ONPG were also solved 
to 2.1 Å and 1.8 Å, respectively. Structural overlay of the apo and ligated crystal structures yields 
root-mean-square deviation (RMSD) values that fall within 0.6 Å, suggesting that FmlHLD 
generally adopts the same active or functional conformational state in the absence or presence of 
ligand (Fig. 1C). This functional conformational state most likely corresponds to a high-affinity 
conformation of FmlH, as the FmlHLD structures exhibit a higher degree of structural homology to 
the high-affinity conformation of FimH (RMSD values of 0.8 to 0.9 Å) than to the low-affinity 
conformation of FimH (RMSD values of 1.7 to 1.9 Å) [34–38]. 
 The cocrystal structure of FmlHLD-TF reveals two copies of FmlHLD-TF in the unit cell, in 
which each TF adopts a distinct ligand conformation (Fig. 1D). In both copies, the terminal Gal in 
TF occupies the cleft of the binding pocket through direct polar interactions with residues F1, D53, 
K132, and N140. In contrast, the orientation of the GalNAc in TF differs significantly between the 
two copies of FmlH. In chain A, the GalNAc sugar points toward loop 3, with the carbonyl group 
of GalNAc forming a hydrogen bond (H-bond) with the guanidinium group of R142. In chain B, 
however, the GalNAc packs against and forms a H-bond with the hydroxyl group of Y46. 
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Accordingly, the differences in the orientation of bound ligand across the two copies are 
accompanied by slight differences in orientation of the side chains of the interacting residues Y46 
and R142. The multiple binding modes observed for a single ligand suggests that the wide, shallow 
nature of the Gal binding pocket in FmlH would enable galactosides to possibly bind FmlH with 
diverse interactions and conformations. 
 The FmlHLD-ONPG cocrystal structure also shows two copies of FmlHLD in the unit cell, in 
which a sulfate ion occupies the binding pocket of chain A while ONPG occupies the binding 
pocket of chain B (Fig. 1D). As expected, the Gal component of ONPG resides in the cleft of the 
binding pocket, while the solvent-exposed nitrophenyl group mediates a polar or salt-bridge 
interaction with R142 through an intricate network of H-bonds with water molecules. Furthermore, 
the positioning of the Gal component of ONPG aligns with that of the Gal residue of TF (Fig. 1C). 
Moreover, the conformation of the FmlH binding pocket observed in this FmlHLD-ONPG cocrystal 
structure resembles the binding pocket conformation in the FmlHLD-TF cocrystal structure, 
reflecting a high-affinity binding orientation that can be targeted for drug discovery. These results 
and observations strongly suggested that the FmlHLD-ONPG cocrystal structure represents an 
appropriate structural candidate for use in virtual screening to aid in the design of galactoside 
compounds specific for FmlH. 
Virtual Screen Identifies and Informs the Design of FmlH-Targeting Galactosides  
 An exhaustive virtual screen was performed using AutoDock Vina to computationally dock 
∼1,800 known galactosides in the binding pocket of FmlHLD (from an FmlHLD-ONPG cocrystal 
structure; PDB ID 6AOY), generating a ranked list of top binding poses and associated docking 
scores for each galactoside (SI Appendix, Fig. S1A). Top hits from the virtual screen were filtered 
according to group efficiency values and then visually inspected to aid and inform structure-guided 
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drug design. In all cases, the Gal component of top-scoring galactosides bound to the cleft of the 
binding pocket, as expected. In addition, most of the high-scoring hits also interacted with specific 
hot-spot residues near the Gal binding pocket, which we sought to leverage for compound 
optimization. These hot-spot residues included (i) residue Y46, which caps the top of the binding 
pocket and can contribute hydrophobic interactions; (ii) residue K132, which lies at the bottom of 
the sugar binding pocket and can engage polar groups linked to the Gal sugar; and (iii) residue 
R142, which points toward an empty, solvent-exposed cleft near the binding pocket and can 
contribute electrostatic interactions (SI Appendix, Fig. S1B). These visual insights were then 
considered in our rational design strategy for FmlH-targeting galactoside antagonists. 
Design and Synthesis of FmlH-Targeting Galactoside Antagonists  
 To increase FmlH binding affinity and explore structure-activity relationships (SARs), we 
constructed a large library of galactoside analogs (Fig. 2). Based on the docking results, we 
predicted that β-Gal isomers would be preferred over α-Gal and that ortho positioning of functional 
groups on a phenyl scaffold would best facilitate interactions with specific sites within the binding 
pocket, namely hot-spot residues Y46 and R142. Accordingly, we synthesized and evaluated small 
sets of phenyl galactosides with ortho-substituted functional groups (2 to 6; Fig. 2A). We also 
either purchased or synthesized several other phenyl galactosides, which contained meta or para 
substituents on the aglycone ring (7 to 11; Fig. 2A), and other aryl and heterocyclic galactosides 
(12 to 22; Fig. 2 B and C). This allowed us to derive meaningful SARs for informing further design 
and optimization of improved galactosides. In addition, we tested natural-product galactosides 
isolated from cranberries and other natural sources (23 to 27; Fig. 2D). The promising activity of 
the simple galactoside ONPG (4β) in the initial screen, coupled with the hot-spot residues 
identified in virtual screening, prompted us to expand our FmlH-ligand design strategy with a 
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compound series containing biphenyl aglycones (28 to 32; Fig. 2E), such as 29β-NAc, the N-
acetyl-β-galactosaminoside with an m-carboxylic acid on the B-ring designed to directly interact 
with the hot-spot residue R142 (SI Appendix, Fig. S1 B and C). To confirm the predicted 
preference for the β-Gal isomers, we also synthesized and tested many corresponding α-Gal 
isomers. Compounds were synthesized by using one of two general synthetic glycosylation 
methods involving either a reaction between Gal pentaacetate and phenols promoted by boron 
trifluoride or a Koenigs–Knorr-type reaction of galactosyl halide with aryl alcohols (SI Appendix, 
Fig. S2). 
Biochemical Characterization of FmlH Antagonists  
 Selected top-hit glycosides and a few low-scoring analogs from the virtual screen, as well as 
synthetic galactosides, were tested in the ELISA-based competition assay for their ability to inhibit 
binding of FmlHLD to ds-BSM. Direct comparison of inhibitory potency among galactosides led 
to delineation of basic SARs (Fig. 3 A–C and SI Appendix, Table S2). When tested at 100 μM, 
the phenyl β-galactoside 1β (beta isomer of 1; Fig. 2A) exhibited significantly higher binding 
inhibition (77%) than Gal (8.1%), indicating that the phenyl group significantly enhances binding 
to FmlHLD (Fig. 3A). Various ortho substituents on the phenyl ring additionally conferred 
substantial improvements in inhibitory potency, as observed with 2β (87%), 3β (95%), 4β (ONPG; 
93%), 5β (97%), and 6β (90%). In contrast, the meta-methoxy groups in compound 7β (76%) did 
not enhance binding strength compared with 1β. Further, para-substituted functional groups 
displayed variable inhibitory potencies relative to 1β, with enhancements observed in 8β (86%) 
and 9β (86%), with no significant effect observed in 11β (78%) or 11β-thio (72%), and with a 
reduction observed in 10β (65%). Thus, we deduced that the ortho-substituted phenyl β-
galactosides generally outperformed other simple phenyl galactosides. 
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 Complex heterocyclic galactosides, such as coumarins 12β (85%) and 14β (89%), which 
differ only by a methyl group, displayed significant inhibitory potencies against FmlHLD, while 
the related galactoside 13β (50%) displayed reduced inhibitory activity, likely because of its fluoro 
substituents (Fig. 3A and SI Appendix, Table S2). Resorufin galactoside 15β (80%) also showed 
similar potency compared with the phenyl β-galactoside 1β. These combined results suggest that 
the substituents of 12β are responsible for augmenting affinity relative to 1β. In contrast, indoles 
16β (22%) and 17β (41%) performed poorly as inhibitors of FmlHLD. Naphthyl galactosides 18β 
(46%) and 19β (79%), in addition to isoquinoline 21β (15%), showed no improvement in activity 
relative to 1β. However, quinoline 20β (95%) displayed significantly higher inhibition than 1β and 
18β. This advocates that the electron pair-donating nitrogen atom in 20β is making a specific 
interaction with FmlH. This observation is consistent with the pattern of SARs, indicating that the 
ortho position is key to enhancing inhibitory potency against FmlHLD. 
 We also evaluated naturally occurring galactosides derived from cranberries and other 
natural sources in this screen (Fig. 3A and SI Appendix, Table S2). These compounds included 
anthocyanidin (pelargonidin, 23β; cyanidin, 24β; peonidin, 25β) and flavonol (quercetin, 26β; 
myricetin, 27β) β-galactosides. Generally, these compounds exhibited moderate to weak inhibition 
of FmlHLD binding, with little enhancement in inhibition relative to Gal (8.1%). The only 
significant binders were 24β (29%) and 26β (14%). Comparison of the anthocyanidin family 
indicates that the 3′ or meta-substituted hydroxyl group on the B-ring of 24β is critical for its 
specific interaction with FmlH. Absence of this meta substituent in 23β (0.7%) or methylation of 
the hydroxyl group in 25β (3.6%) abrogates potency, suggesting that the hydroxyl group of 24β 
might participate in a H-bond to a specific residue in the FmlHLD binding pocket. Additional 
inhibitory screens performed with cranberry-derived compounds and fractions at 1 mM confirmed 
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the specificity and necessity of the Gal sugar for inhibiting the binding pocket of FmlH (SI 
Appendix, Fig. S3 A and B). 
 Interestingly, the tested GalNAc-derived compounds possessed significantly higher 
inhibitory potency compared with their matched-pair Gal-derived counterparts, as exemplified 
with 4β-NAc (87%) relative to 4β (31%) when tested for inhibition at 10 μM (Fig. 3B and SI 
Appendix, Table S2). These results taught us that the N-acetyl group, together with other 
functional groups, contributes to binding by targeting distinct components of the binding pocket 
of FmlH. In contrast, the galactosides with α-linkages (28α-30α) or disaccharides with aglycone 
moieties (33 to 35) were generally poor inhibitors of FmlH, except for 11α-NAc (82%) (Fig. 3A 
and SI Appendix, Table S2). 
 Consistent with the above-mentioned SARs, the ortho biphenyl galactoside 28β (91%) was 
more potent than the meta 31β (57%) or para 32β (30%) analogs (Fig. 3A and SI Appendix, Table 
S2). Next, we installed a carboxylate group at the meta position on the biphenyl B-ring (29β), 
intended to target the pocket formed by N140 and R142, and found that 29β exhibited greater 
inhibition (99%) compared with 28β when tested at 100 μM. This pronounced difference in activity 
was further highlighted when these compounds were tested for inhibition at 10 μM and 1 μM (Fig. 
3 B and C and SI Appendix, Table S2). Importantly, 30β (87%), the methyl ester of 29β, tested at 
100 μM resulted in a reduction in binding, suggesting that the negative charge of the carboxylic 
acid likely mediates a critical electrostatic interaction with R142 of FmlHLD. Lastly, we 
synthesized the GalNAc version of 29β to increase its binding affinity and found that 29β-NAc 
(93%) had significant improvement in activity over 29β (75%) when tested at 10 μM. Final 
evaluation of the highest performing galactosides in the ELISA-based competition assay at 
concentrations of 10 μM and 1 μM allowed for a clearer ranking of compounds, where 29β-NAc 
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clearly stood out as the most potent (Fig. 3 B and C and SI Appendix, Table S2). 
Determination of FmlH–Galactoside Binding Affinities  
 Bio-layer interferometry (BLI) was pursued to quantitate the binding affinity of the most 
promising FmlH antagonists. First, biotinylated serine-linked TF (Ser-TF) immobilized on 
streptavidin pins was incubated with varied titrations of FmlHLD in solution, and steady-state 
analysis of binding responses revealed a dissociation constant (Kd) of 15.0 ± 0.8 μM (Fig. 3D). 
Next, immobilized Ser-TF was incubated in solutions comprising a fixed concentration of FmlHLD 
but varying concentrations of galactosides to determine their inhibitory or dissociation constant 
(Ki or Kd) values (Fig. 3E). The BLI-based affinity determinations correlated well with the relative 
binding strengths measured in the ELISA-based competition assay (Fig. 3 A–C and SI Appendix, 
Table S2). The two lead compounds, 29β-NAc and 29β, bound tightly to FmlHLD, with respective 
Ki values of ∼90 nM and 2.1 μM, which represent a ∼7,800-fold and ∼330-fold enhancement in 
binding affinity relative to Gal. Another promising compound, 4β-NAc, bound FmlHLD with a Ki 
value of 2.3 μM. In summary, a combinatorial approach based on virtual screening and structure-
guided ligand design led to the discovery of small–molecular weight monomeric glycosides 
derived from Gal and GalNAc that function as effective antagonists of FmlH. Optimization of 
early hits to high-affinity o-biphenyl Gal and GalNAc antagonists was realized via ortho 
substitution on phenyl aglycones to facilitate interactions that significantly enhanced binding to 
FmlH. 
Structural Basis of Galactoside Inhibition of FmlH  
 To elucidate the molecular basis for galactoside inhibition of FmlH, cocrystal structures of 
FmlHLD bound to 4β, 5β, 20β, and 29β-NAc were determined (Fig. 4 A and B). These galactosides 
share a common aglycone motif consisting of a phenyl ring with an ortho-substituted functional 
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group. As predicted from computational studies, the sugar portion of all these galactosides resides 
within the cleft of the binding pocket. The phenyl groups directly attached to the sugar portion of 
all four compounds lie along the same 3D plane. In this nearly identical conformation, the phenyl 
ring is oriented perpendicularly to the side chain of residue Y46, revealing edge-to-face π-stacking, 
which likely contributes to the affinity enhancement observed for all β-galactosides. For 4β, 5β, 
and 20β, the ortho substituents point toward R142 but are too distant (>7 Å) for direct interaction 
and, instead, form H-bonds with water molecules that, in turn, interact with residues K132 and 
R142 (Fig. 4A). Thus, we deduced that the marked affinity enhancement observed for 4β, 5β, and 
20β is due to a combination of (i) indirect interactions between the ortho substituent and residues 
K132 and R142 formed by an intricate network of water-mediated H-bonds and (ii) edge-to-face 
π-stacking between the phenyl ring and residue Y46. 
 In contrast to simple phenyl galactosides, the biphenyl scaffold of 29β-NAc presents the 
carboxylic acid to engage in a direct charge–charge interaction with the guanidinium side chain of 
R142 (Fig. 4B). The lower potency of the methyl ester derivative 30β is further evidence that the 
charge–charge interaction likely drives the observed affinity enhancement (Fig. 4C). The improved 
affinity of 29β-NAc relative to 29β is also due to additional interactions mediated by the N-acetyl 
group in H-bonding to a water molecule captured by the biphenyl aglycone and the side chain of 
residue K132 (Fig. 4 B and C). Altogether, analysis of all X-ray crystal structures of ligand-bound 
FmlH offers two general mechanisms for the significant enhancement in binding affinity of 
galactosides relative to Gal: edge-to-face π-stacking with Y46 and polar or electrostatic charge–
charge interactions with K132 and R142. 
FmlH Antagonist Effectively Treats Murine UTI in Vivo and Prevents Binding to Human 
Kidney Tissue  
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 We previously reported that FmlH binds to naïve kidney and inflamed bladder tissue and 
plays a critical role in chronic UTI, as abrogation of its function through genetic deletion or 
vaccination results in significant attenuation in the ability of UPEC to cause chronic UTI [34]. 
Thus, we hypothesized that galactosides that inhibit the function of FmlH would have efficacy in 
the treatment and/or prevention of UTI. To assess therapeutic potential, the lead compound 29β-
NAc was evaluated for its ability to reduce bacterial burdens in the urinary tracts of C3H/HeN 
mice during chronic UTI. We previously defined chronic cystitis in C3H/HeN mice as urine titers 
of >104 CFU/mL lasting at least 2 to 4 wk, as well as bladder inflammation and edema at euthanasia 
[39]. Further, C3H/HeN mice are genetically predisposed to vesicoureteral reflux (retrograde flow 
of urine from the bladder to the kidneys), which can lead to bacterial colonization of the kidneys, 
renal abscess formation, scarring, and atrophy [40]. Accordingly, we observed high levels of 
kidney colonization by CFT073 in control (vehicle-treated) animals. When delivered 
intravesically, 29β-NAc significantly reduced bacterial burdens in both the bladder and the kidneys 
of these mice (Fig. 5 A and B). For comparison, mannoside 4Z269, which inhibits the type 1 pilus 
adhesin FimH, also significantly reduces titers of CFT073 from the bladders and kidneys of 
infected mice relative to vehicle control (Fig. 5 A and B). When administered together, 29β-NAc 
and 4Z269 eradicated bacteria from the kidney in nearly all mice while also reducing bacterial 
titers in the bladder, suggesting that FimH mannosides and FmlH galactosides may function 
synergistically to target distinct bacterial adhesins or communities within the kidney habitat (Fig. 
5 A and B). 
 To show relevance to human UTI, we assessed FmlH and FmlH-targeting galactosides 
through immunofluorescence analysis of FmlHLD binding to human kidney and bladder biopsied 
tissue determined to be nonmalignant. While FmlHLD does not appear to bind to healthy human 
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bladder tissue, FmlHLD does bind to healthy human kidney tissue, particularly in regions 
resembling the collecting ducts and distal tubules of the kidney (Fig. 5C and SI Appendix, Figs. 
S4 and S5). As a negative control, the binding null mutant FmlHLD K132Q, which lacks the ability 
to bind ds-BSM in vitro (SI Appendix, Fig. S6), was incapable of binding kidney tissue, suggesting 
that FmlHLD specifically recognizes receptors naturally present in human kidney tissue (Fig. 5C). 
These observations are consistent with the previously reported binding phenotypes in mice, in 
which FmlH can bind naïve mouse kidney tissue, but not naïve mouse bladder tissue, and can bind 
to receptors in inflamed bladder tissue [34]. Moreover, incubation of 29β-NAc with FmlHLD 
prevented binding to human kidney tissue, suggesting that these results may translate to humans. 
Importantly, these collective data provide substantial evidence that aryl glycoside–based FmlH 
antagonists derived from β-Gal or β-GalNAc can serve as an effective therapy for persistent UTIs, 
including pyelonephritis, for which there is an enormous unmet medical need. 
 
Discussion 
 UPEC is the causative agent of most UTIs, a common and very costly disease in women, 
children, and the elderly that is becoming increasingly resistant to antibiotic treatment. By 
leveraging our expertise in UPEC pathogenesis and structure-based drug design, we developed 
small-molecule Gal-based FmlH antagonists that show in vivo efficacy in the treatment of chronic 
UTI in mouse models. Virtual screening combined with rational design led to the identification of 
several naturally occurring cranberry and synthetic galactosides, the most potent of which binds 
FmlH with nanomolar affinity. X-ray crystallography revealed that potent galactosides achieve 
significant enhancements in binding affinity through interactions on opposite sides of the wide Gal 
binding pocket of FmlH. Appropriately substituted aryl groups, like those found in 4β/4β-NAc, 
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5β, and 20β, are seen to mediate edge-to-face π-stacking interactions with Y46 of FmlHLD. Further, 
the optimized biphenyl aglycone of compound 29β-NAc contains an ideally positioned carboxyl 
group to mediate electrostatic interactions with R142 in addition to π-stacking interactions with 
Y46. Evaluation of the lead candidate 29β-NAc in a mouse model of chronic UTI demonstrated 
significant reductions of bacterial burdens in the mouse kidney and bladder. Combination dosing 
with mannoside and galactoside resulted in near complete clearance of bacteria from the kidney 
and significant elimination of bacteria from the bladder. Furthermore, FmlH was shown to bind 
specifically to human kidney tissue, which could be inhibited by 29β-NAc. Additionally, FmlH 
has been shown to be up-regulated in urine samples directly isolated from human patients with 
UTI compared with expression during in vitro growth in media or normal urine [41], suggesting 
an important role for FmlH in human UTI. Thus, FmlH-targeting galactosides represent a rational 
antivirulence modality for the effective treatment of UPEC-mediated UTI. 
 Our rational strategy to discover receptor-mimicking galactosides targeting FmlH was 
similar to the strategy we followed for the development of FimH mannosides. However, the design 
of the galactoside and N-acetylgalactosaminoside antagonists of FmlH was met with distinct 
challenges. The most striking difference between FmlH and FimH is the binding affinity for their 
respective ligands: FimH binds soluble Man with a moderate binding affinity of ∼5 to 10 μM, and 
FmlH binds soluble Gal with a weak binding affinity of ∼700 μM [34, 42, 43]. The weak binding 
affinity of FmlH, which is quite common for most carbohydrate–lectin interactions, rendered the 
development of high-affinity galactosides much more challenging. This disparity in affinity is a 
direct consequence of the substantial variance in the shape of the binding pocket. FimH binds Man 
with high affinity because of the deep, narrow pocket formed by loops 1, 2, and 3, in which loops 
2 and 3 mediate specific polar interactions directly to Man and a water molecule and loop 1 serves 
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as an affinity clamp to stymie dissociation of Man [35]. In contrast, loop 1 in FmlH is more distant 
from loops 2 and 3 than it is in FimH and does not contribute to binding, which results in a widened, 
solvent-exposed pocket for weak Gal binding (Fig. 1D). In addition, the differences in binding 
pocket architecture dictate the sterically allowed linkage types. FimH has space at the tip of the 
LD between its parallel tyrosine gate (residues Y48 and Y137) to accept α-linked moieties, of 
which biaryl groups confer drastic enhancements in affinity through strong parallel face-to-face π-
stacking interactions. In contrast, FmlH is capped at the very tip of the pocket with Y46, which 
biases specificity toward β-linked moieties, of which biaryl groups confer moderate enhancements 
in affinity through significant edge-to-face π-stacking interactions. Having accounted for these 
variations, our structure-guided medicinal chemistry approach, coupled with our in vivo work, has 
clearly demonstrated the future translational impact of galactosides as treatments for UTI. 
 It is noteworthy that our collective search for high-affinity antagonists of FmlH and FimH 
has led to discovery of biphenyl moieties as the preferred aglycone groups for high-affinity 
galactosides and mannosides, respectively. Pocket geometry dictates the type of biphenyl scaffold 
that is optimal. Thus, the best FimH-targeting mannosides contain para biphenyls in the alpha 
stereochemistry, while the best FmlH-targeting galactosides contain ortho biphenyls in the beta 
orientation. However, in both cases, H-bonding donors or acceptors on the B-ring result in 
significant enhancement in binding affinity through specific interactions outside the sugar binding 
pocket. Intriguingly, the inhibitory potency conferred by the meta carboxyl on the B-ring of 29β-
NAc is also appreciated in the significant inhibitory role of the meta-substituted group on the B-
ring in cranberry compounds 24β and 26β, which suggests a common pharmacophore between our 
optimal synthetic compound and natural-product compounds in targeting FmlH. This study 
provides evidence that specific glycosidic compounds in cranberry can specifically bind and 
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inhibit a bacterial adhesin. Furthermore, our work exposes a trend indicating that π-stacking of 
aromatic aglycones with binding pocket residues in the adhesin is essential in mimicking 
glycoprotein receptors and for developing tight-binding ligands in each lectin. Mimicking 
carbohydrates with small molecules is a long-sought-after goal in medicinal chemistry and 
chemical biology [44-46], and we believe that these results add significantly to this understanding 
and goal. This information can now be utilized not only in the future optimization of lead 
compound 29β-NAc as a treatment for UTIs, but also in the rational design of numerous other 
lectin antagonists for the development of small-molecule glycoside-based drugs aimed at treating 
infections mediated by E. coli or other microbes [44]. 
 The rapid increase and spread of antibiotic resistance, including multidrug-resistant forms of 
bacteria, has rendered many antibacterial therapies ineffective and threatens to undermine the 
biomedical strides made to promote human health and longevity [9]. Selection pressures imposed 
by antibiotics on bacterial pathogens have promoted their proliferation, especially through overuse 
of antibiotics within the farming industry and inappropriate use or misuse among patients [47-50]. 
Recent reports indicate that patients are now succumbing to bacterial strains which possess broad-
spectrum resistance to all last-resort antibiotics, which many fear signals that antibiotic resistance 
will pave the way for the “next pandemic” [15]. Antivirulence strategies that aim to reduce the 
pathogenicity of bacterial pathogens promise to provide the same therapeutic efficacy as 
antibiotics without introducing selective pressures that would promote widespread dissemination 
of resistance [16]. Multiple antivirulence efforts will be required to combat the multiple 
mechanisms by which diverse bacterial pathogens colonize the host, which can include, for 
example, the targeting of CUP pilus adhesins or the biogenesis machinery responsible for the 
assembly of CUP pili [51]. As highlighted in this work, UPEC employs an armament of diverse 
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CUP pili to colonize and persist within changing local environments encountered during UTI 
pathogenesis, which suggests that targeting more than one CUP adhesin may indeed be a more 
effective strategy for combating UTIs. Herein, we have highlighted the overwhelming value of 
applying a deep mechanistic understanding of structure-function-virulence relationships of 
bacterial adhesins to the rational design of high-affinity carbohydrate glycomimetics for the 
treatment of UTI. This demonstration serves as a general model for the rational approach necessary 
to target virulence factors and disrupt their role in bacterial infections. 
 
Materials and Methods 
Ethics Statement 
 All animal experiments were conducted according to the National Institutes of Health (NIH) 
guidelines for housing and care of laboratory animals and performed in accordance with 
institutional regulations after pertinent review and approval by the Institutional Animal Care and 
Use Committee at Washington University School of Medicine (protocol 20150226). Deidentified 
human tissue was obtained from the Tissue Procurement Core at Washington University School 
of Medicine. 
Protein Expression and Purification 
 FmlH residues 1 to 160 from UPEC strain UTI89 with a C-terminal six-histidine tag (i.e., 
FmlHLD) were cloned into the IPTG-inducible plasmid pTrc99A. This construct was then 
transformed into and expressed in E. coli strain C600. Periplasms were isolated as previously 
described and dialyzed four times against PBS plus 250 mM NaCl [34]. FmlHLD was purified from 
this periplasmic fraction by cobalt affinity chromatography through elution with 150 mM 
imidazole. FmlHLD was buffer exchanged into 10 mM Hepes [4-(2-hydroxyethyl)-1-
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piperazineethanesulfonic acid] (pH 7.5) and 50 mM NaCl, concentrated to 6 mg/mL, and stored 
stably at 4 °C for use in biochemical and biophysical assays. 
In Silico Docking and Virtual Screening 
Structure-based virtual screening through in silico docking was performed with AutoDock 
Vina [52]. Existing Gal-based derivatives were identified through the ZINC12 database [53]. Their 
3D structures were extracted from the downloaded mol2 file as pdb coordinates and converted to 
pdbqt format using Open Babel [54]. The crystal structure of apo FmlH was converted to its 
topology file using AutoDock Tools. The grid box was centered at the Gal binding pocket of FmlH, 
and its dimensions (26 × 26 × 26 Å3) were chosen to accommodate bulky compounds and multiple 
potential binding modes at or near the binding pocket. The exhaustiveness of the search was set to 
a value of 15. The top binding modes and scores within this grid space were generated by 
AutoDock Vina. Custom in-house scripts in Bash and MATLAB were used to link these binding 
scores with compound properties such as molecular weight. Top binding modes were visualized 
in PyMOL. 
Virtual screening of this library, which comprised galactosides ranging from 150 to 900 
Da in molecular mass, yielded a mean docking score of 6.3 kcal/mol (1 kcal = 4.18 kJ), with a 
standard deviation of 0.73 kcal/mol and a range of 4 to 9 kcal/mol (SI Appendix, Fig. S1A). To 
prioritize hits, we abstained from directly comparing raw binding scores, as large, lipophilic 
molecules tend to have artificially high predicted binding interactions due to their contribution to 
hydrophobic interactions as calculated by the empirical scoring function of AutoDock Vina [52]. 
Instead, the results of the virtual screen were evaluated per group efficiency (GE), which, in this 
context, measures the contribution of the aglycone group within each galactoside (indicated as X 
in the following equation) to the docking score (DS) with respect to the number of heavy atoms 
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(HA) present in the aglycone group [GE = (DSX − DSGal)/(HAX − HAGal)]. Top hits were defined 
as galactosides with a GE value greater than 1.25 times the SD (σ = 0.0016 kcal/mol per HA) 
above the library mean (μ = 0.0011 kcal/mol per HA), which constituted the top ∼10% of highest 
scoring galactosides (SI Appendix, Fig. S1A). 
Synthesis of Galactosides and N-acetyl Aminogalactosides 
Galactosides and N-acetyl aminogalactosides were synthesized by standard glycosylation 
chemistry, including boron trifluoride-mediated glycosidation and the Koenigs–Knorr reaction, 
respectively (SI Appendix, Fig. S2). In method A, boron trifloride-promoted glycosylation of 
phenols with Gal pentaacetate yielded corresponding acetylated aryl galactosides, which were 
treated with sodium methoxide in methanol to provide the corresponding aryl galactosides (1β to 
3β, 5β to 9β, 18β to 19β, and 28β to 32β; 2α to 3α, 18α to 19α, and 28α to 32α). In method B, final 
GalNAc and Gal analogs (20β-NAc, 21β, 28β-NAc, and 29β-NAc) were synthesized from 
galactosyl halide and aryl alcohols via a Koenigs–Knorr-type reaction, which yielded aryl 
galactosides that were then deacetylated by treatment with methylamine in ethanol. 
ELISA 
 Immulon 4HBX 96-well plates were coated overnight with 1 μg of bovine submaxillary 
mucin (Sigma). Coated wells were then treated with 100 μL of Arthrobacter ureafaciens sialidase 
(10 mU/mL) diluted in PBS for 1 h at 37 °C. Thereafter, wells were incubated with 200 μL of 
blocking buffer (PBS plus 1% BSA) for 2 h at 23 °C, followed by incubation with 100 μL of 
biotinylated FmlHLD diluted in blocking buffer to 20 μg/mL in the presence or absence of 
galactoside compounds for 1 h at 23 °C. After washing three times with PBS plus 0.05% TWEEN-
20, 100 μL of streptavidin-HRP conjugate (BD Biosciences; 1:2,000 dilution in blocking buffer) 
was added to each well for 1 h at 23 °C. After a final round of washing, plates were developed 
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with 100 μL of tetramethylbenzidine (BD Biosciences) substrate and quenched within 1 to 2 min 
with 50 μL of 1 M H2SO4, and absorbance was measured at 450 nm. This assay was used to 
determine percent inhibition values and inhibitory constant (IC50) values where indicated. 
BLI 
 Streptavidin pins were first dipped in a baseline in PBS (pH 7.4) for 120 s, followed by 
loading of 5 to 10 μg/mL biotinylated Ser-TF (Toronto Research Chemicals) in PBS for 300 s, 
quenching by 10 μg/mL biocytin in PBS for 240 s, and another baseline step in PBS for 120 s. 
Thereafter, pins were dipped in PBS for 120 s and transferred to protein samples (varying 
concentration of FmlHLD or fixed concentration of FmlHLD with varying concentration of 
galactoside compounds) for association for 300 to 600 s. Equilibrium binding response values were 
used to determine the affinity of interaction between FmlHLD and immobilized Ser-TF under a 1:1 
binding model or between FmlHLD and galactosides in solution under a competitive one-site 
binding model. 
Protein Crystallization and Structure Determination 
 Crystals of apo FmlHLD in 10 mM Hepes (pH 7.5) and 50 mM NaCl were grown by mixing 
2 μL of protein (6 mg/mL) with 2 μL of mother liquor [0.2 M ammonium sulfate, 0.1 M NaCl, 0.1 
M Mes [2-(N-morpholino)ethanesulfonic acid] (pH 5.6), and 28% PEG 3350] and equilibrated 
against 1 mL of mother liquor in the reservoir. Cocrystals of FmlHLD bound to TF or galactosides 
4β (in space group P 2 21 21), 5β, and 20β were grown by mixing 2 μL of protein (6 mg/mL) in 
the presence of 5 mM compound with 2 μL of mother liquor [0.2 M ammonium sulfate, 0.1 M 
NaCl, 0.1 M Mes (pH 5.6), and 32% PEG 3350] and equilibrated against 1 mL of mother liquor 
in the reservoir. These crystals were transferred into cryoprotectant [0.2 M ammonium sulfate, 0.1 
M NaCl, 0.1 M Mes (pH 5.6), 35% PEG 4000, and 10% glycerol] and then flash frozen in liquid 
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nitrogen. Cocrystals of FmlHLD bound to the galactoside 29β-NAc were grown by mixing 2 μL of 
protein complex (10 mg/mL FmlHLD with a 1.2:1 molar ratio of 29β-NAc to FmlHLD) with 2 μL 
of mother liquor (0.7 M LiSO4 and 2% PEG8000) and equilibrated against 1 mL of mother liquor 
in the reservoir. These crystals were transferred into cryoprotectant (1 M LiSO4, 10% PEG8000, 
and 25% glycerol). Diffraction data for TF, 4β (in space group C 1 2 1), and 29β-NAc structures 
were collected at 100 K at an in-house facility equipped with a rotating anode Rigaku MicroMax 
007 generator, a Rayonix Marmux X-ray source, and a Mar345 image plate detector. Diffraction 
data for apo, 4β, 5β, and 20β structures were collected at 100 K at the ALS Beamline 4.2.2. Data 
were indexed and integrated in iMosflm [55], XDS [56], or HKL2000 and scaled by Scala [57]. 
The phase problem was solved by molecular replacement using Phaser-MR in PHENIX [58] with 
FimHLD from PDB ID 3MCY. Several rounds of refinements were performed in PHENIX to 
improve the final models. 
Mouse Infections 
 Seven- to 8-wk-old female C3H/HeN mice were obtained from Envigo. Mice were 
anesthetized and inoculated via transurethral catheterization with 50 μL of CFT073 bacterial 
suspension (∼1 × 108 to 2 × 108 CFU in total) in PBS. Mice experiencing high titers of bacteriuria 
(>104 CFU/mL) and edematous and inflamed bladders when killed after 2 wk, or chronic cystitis 
[39], were then transurethrally inoculated either with 50 mg/kg compound or vehicle control (10% 
DMSO). Mice were killed 6 h posttreatment, and bacteria colonizing the bladder or kidney were 
plated for quantification. 
Immunofluorescence 
 Frozen, deidentified human bladder and kidney sections were obtained from the Tissue 
Procurement Core and stored stably at −80 °C. These tissue section slides were removed from the 
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freezer and allowed to thaw at room temperature for 10 to 20 min. After applying a hydrophobic 
barrier pen around the tissue, slides were rehydrated in 200 μL buffer (5% BSA and 0.2% Triton 
X-100 in PBS) for 10 min. Buffer was gently aspirated and slides were blocked for 1 h at room 
temperature with 200 μL of buffer. Thereafter, buffer was gently aspirated and slides were 
incubated with 200 μL of sample overnight at 4 °C. Samples diluted in buffer included 50 μg/mL 
FmlHLD wild-type (WT), 50 μg/mL FmlHLD K132Q, and 50 μg/mL FmlHLD WT incubated with 
100 μM 29β-NAc. Samples were gently aspirated and slides were washed three times in buffer for 
5 min each. Next, slides were incubated with our mouse anti-FmlH polyclonal antibody (1:500 
dilution in buffer) for 1 h at room temperature. Slides were washed again three times in buffer and 
then incubated in the dark with donkey anti-mouse IgG Alexa Fluor 594 and Wheat Germ 
Agglutinin Alexa Fluor 633 (each 1:500 dilution in buffer) for 1 h at room temperature. Slides 
were washed once with buffer and then incubated in the dark with DAPI (1:1,000 dilution in 
buffer) for 5 min at room temperature. After washing twice with buffer, coverslips were mounted 
using 80 μL of mounting media. Slides were loaded onto a Zeiss LSM 880 Confocal Laser 
Scanning Microscope (Carl Zeiss, Inc.) equipped with a diode 405 to 430 laser, a HeNe 543 laser, 
and a HeNe 633 laser. Images were acquired with a 20×, 0.8 numerical aperture Zeiss Plan 
Apochromat objective using ZEN 2 imaging software. 
Statistics 
 Mouse data are compiled from two (4Z269 plus 29β-NAc) or three (all other treatments) 
independent experiments, with four or five mice per group per experiment. These data were 
analyzed using the uncorrected two-tailed Mann–Whitney U test in GraphPad Prisim v.5. ELISA 
data are reported as box-and-whisker plots indicating the mean, 2.5th, 25th, 75th, and 97.5th 
percentiles of at least two independent experiments, with three technical replicates per experiment. 
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Figure 1. Biochemical and structural characterization of early galactoside antagonists of FmlH. 
(A) Strategy for structure-guided drug design and evaluation of FmlH-targeting galactosides. A 
select library of galactosides were initially assessed in an ELISA-based competition assay for 
inhibition of FmlH binding to sialidase-treated BSM, with BSM indicated by gray circles, TF 
residues indicated by the yellow square-circle conjugates, biotinylated FmlHLD by blue rectangles, 
and galactosides shown as colored circles. Cocrystal structures of FmlHLD bound to a lead 
compound facilitated virtual screening and structure-guided drug design for biochemical 
evaluation of an expanded galactoside library. The top lead compound would then be tested as a 
treatment in a mouse model of UTI. (B) ELISA-based competition assay performed in triplicate in 
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the absence or presence of 1 mM or 0.1 mM compounds with at least two biological replicates. 
Data are reported as the mean percent inhibition, with the box indicating the 25th to 75th 
percentiles and the whiskers indicating the 2.5th and 97.5th percentiles. (C) Structural alignment 
of FmlHLD from an apo FmlHLD crystal structure (PDB ID 6AOW), a FmlHLD-TF cocrystal 
structure (PDB ID 6AOX), and a FmlHLD-ONPG cocrystal structure (PDB ID 6AOY). (D) Crystal 
structures of sulfate ions or ligands bound in the FmlHLD binding pocket, with H-bonding (black 
dashed lines) indicated between sulfate ions (yellow sticks), ligands (green sticks), water 




































Figure 2. Grouped organization of galactosides evaluated for FmlHLD inhibition. The major 
groups include the phenyl (A), heterocyclic (B), napthyl/quinoline/phenylethyl (C), natural 





Figure 3. In vitro screening and affinity determination of galactosides against FmlHLD. (A–C) 
ELISA-based competition assay performed in triplicate in the absence or presence of (A) 100 μM, 
(B) 10 μM, and (C) 1 μM compounds with at least two biological replicates. Data are reported as 
the mean percent inhibition, with the box indicating the 25th to 75th percentiles and the whiskers 
indicating the 2.5th and 97.5th percentiles. a, α; b, β. (D, Left) Schematic of conventional BLI 
experiment, in which pins coated with streptavidin (orange stars) are loaded with biotinylated Ser-
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TF (gray ovals and yellow square-circle conjugates) and dipped into solutions of varying 
concentrations of FmlHLD (blue rectangles). (Right) Equilibrium analysis of soluble FmlHLD 
binding to immobilized Ser-TF according to a 1:1 binding model. (E, Left) Schematic of 
competitive BLI experiment, in which streptavidin-coated pins are dipped into a solution 
composed of a fixed concentration of FmlHLD in the presence of varying concentrations of 
galactoside (yellow circles). (Right) Equilibrium constants of soluble galactoside-mediated 























Figure 4. Structural basis of galactoside inhibition of FmlHLD. (A) Crystal structures of sulfate 
ions or galactosides bound in the FmlHLD binding pocket, with H-bonding (black dashed lines) 
indicated between sulfate ions (yellow sticks), ligands (green sticks), water molecules (red 
spheres), or side chains (pink sticks). Crystal structures shown here include an apo FmlHLD crystal 
structure (PDB ID 6AOW), a FmlHLD-4β cocrystal structure (PDB ID 6ARM), a FmlHLD-5β 
cocrystal structure (PDB ID 6ARN), and a FmlHLD-20β cocrystal structure (PDB ID 6ARO). (B) 
Cocrystal structure of 29β-NAc bound to FmlHLD (PDB ID 6AS8). (C) SARs for 29β-NAc and 
related compounds, with their corresponding IC50 values derived from the ELISA-based 




















Figure 5. Evaluation of galactosides for treatment of UTI and relevance in humans. (A and B) 
Bacterial titers in bladders (A) or kidneys (B) from C3H/HeN mice experiencing chronic cystitis 
transurethrally inoculated with 10% DMSO (three replicates, n = 13), or 50 mg/kg of 4Z269 (three 
replicates, n = 13), of 29β-NAc (three replicates, n = 14), or of both 4Z269 and 29β-NAc (two 
replicates, n = 9). Bars indicate median values. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001; ns, not significant; two-tailed Mann–Whitney U test. (C) Immunofluorescence analysis of 
FmlHLD WT, FmlHLD K132Q, or FmlHLD WT in the presence of 29β-NAc binding to human 
bladder or human kidney tissue. Green corresponds to FmlH, red corresponds to Wheat Germ 
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Agglutinin, and blue corresponds to DAPI. Each image is representative of nine total images (three 




















Figure S1. Virtual screen and structure-guided design of galactosides targeting FmlHLD. (A) 
Summary of virtual screen of galactosides against FmlHLD, in which the docking score of the top 
predicted binding mode is plotted against the molecular weight for each galactoside. Compounds 
with GE values 1.25σ above the mean are colored blue while compounds with GE values below 0 
are colored red. (B) Surface representation of FmlHLD with hot spot residues Y46, K132, and R142 
colored green, blue, and pink, respectively. Hot spot residues were identified as common targets 
observed in the binding modes of the top compounds from virtual screening. (C) Chemical 
structure of compound 29β-NAc, with the carboxylic acid in pink designed to interact with R142, 
the phenyl ring in green designed to interact with Y46, and the N-Acetyl group in blue designed 










Figure S2. Synthesis of galactoside-based FmlH ligands. (A) Boron trifluoride promoted 
glycosidation reaction of protected galactose followed by deprotection to yield galactosides. (B) 
Koenigs-Knorr type reaction followed by deprotection for the substitution of a galactosyl halide 










Figure S3. Cranberry-derived galactosides can inhibit FmlH. (A) Cranberry-derived compounds 
and fractions were tested at 1 mM in the ELISA-based competition assay for inhibition of FmlHLD. 
(B) As a control, cranberry-derived compounds and fractions were tested at 1 mM in the ELISA-
based competition assay for inhibition of FimHLD. The identifies of the compounds indicated 
above are as follows: 1 (quinic acid), 2 (gallic acid), 3 (p-coumaric acid), 4 (2,4-dihydrobenzoic 
acid), 5 (protocatechuic acid), 6 (ferulic acid), 7 (vanillic acid), 8 (catechin), 9 (epicatechin), 10 
(quecetin), 11 (quercitrin), 12 (quercetin galactoside; 26β) 13 (myricetin), 14 (myricetrin), 15 
(cranberry fraction 1 – oligosaccharide), 16 (cranberry fraction 2 –anthocyanins/flavonols), 17 
(cranberry fraction 3 mixed-sized proanthocyanidins), 18 (cyanidin arabinoside), 19 (cyanidin 




Figure S4. Immunofluorescence analysis of FmlHLD WT, FmlHLD K132Q, or FmlHLD WT in the 
presence of 29β-NAc binding to human bladder tissue. Green corresponds to FmlH, red 






Figure S5. Immunofluorescence analysis of FmlHLD WT, FmlHLD K132Q, or FmlHLD WT in the 
presence of 29β-NAc binding to human kidney tissue. Green corresponds to FmlH, red 





Figure S6. Mutagenesis of FmlH binding pocket abrogates function. Varying concentrations of 














Table S1. Data collection and refinement statistics 
 
 
aRmerge = Σhkl Σi |Ii(hkl)-<I(hkl)>|/Σhkl ΣiIi(hkl), where the sum i is over all separate 
measurements of the unique reflection hkl. 
bRpim =  Σhkl [1/(n-1)]1/2 Σi|Ii(hkl)–<I(hkl) >|/Σhkl Σi Ii(hkl) 
bRwork = Σhkl ||Fobs| - |Fcalc||/ Σhkl |Fobs| 
cRfree, calculated the same as for Rwork but on the 5% data randomly excluded from the refinement 
calculation. 





Table S2. Galactoside inhibition of FmlH 
 
 
Percent inhibition (PI) values are reported as the mean with standard error of the mean for 
galactosides tested at 100 μM (PI100), 10 μM (PI10), and 1 μM (PI1) in the ELISA-based 
competition assay. Compounds indicated above not shown in Figure S1 include 33 (p-nitrophenyl 
Gal-β1-3-GalNAc), 34 (p-nitrophenyl Gal-β1-3-GlcNAc), 35 (p-nitrophenyl Gal-β1-6-Gal), and 
36β-thio (IPTG). The “thio” designation indicates a sulfur linkage between the sugar and the 
aglycone group, the “phospho” designation indicates a phosphate group attached the C6-hydroxyl 














































The global emergence and dissemination of antibiotic resistance among Gram-negative 
pathogens has crippled the ability of current last-resort therapies to effectively treat bacterial 
infections, including urinary tract infections (UTIs). This has become a looming worldwide crisis 
that has prompted the development of novel treatment and prevention strategies for infections, 
including the targeting of bacterial virulence mechanisms. Extracellular fibers termed chaperone-
usher pathway (CUP) pili are critical virulence factors in a wide variety of pathogenic Gram-
negative bacteria, functioning in adherence and invasion of host tissues and in biofilm formation 
on medical devices and body habitats. These fibers are each assembled by an outer membrane β-
barrel usher from multiple pilus subunits properly folded by a periplasmic chaperone. There are 
more than a hundred different types of CUP pili, which mediate a considerable range of biological 
tropisms, frequently, through presentation of two-domain adhesins at the distal pilus tip. These 
adhesins have a lectin domain, which often recognizes a specific carbohydrate receptor, and a pilin 
domain to anchor the adhesin to the pilus. The type 1 pilus adhesin FimH, for example, binds 
mannosylated receptors on the bladder epithelium, mediates invasion of superficial facet cells, and 
promotes formation of biofilm-like collections termed intracellular bacterial communities (IBCs), 
all critical events in the establishment of urinary tract infection (UTI) by uropathogenic E. coli 
(UPEC). Studies that uncovered allelic variation in FimH among clinical UPEC isolates, which 
drastically impacts FimH function and virulence, have challenged our understanding of the FimH 
structure-function relationship, necessitating new approaches to understand the mechanisms of 
adhesin function and the pathogenic correlates of allelic diversity. Furthermore, UPEC encode 
several CUP adhesins, including FmlH and SfaH, which presumably confer distinct tropisms but 
remain poorly characterized. The work presented in this thesis uncovers the structural basis of 
UPEC adhesion in the urinary tract mediated by distinct CUP adhesins. I have discovered that 
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positively selected residues in FimH alter a pre-existing equilibrium of two conformational states 
to fine-tune mannose binding strength and host-pathogen interactions in order to optimize 
persistence in the bladder during UTI. Further, I defined the structural basis of the FimH-like 
adhesin FmlH in binding to galactose-containing receptors exposed in kidneys and inflamed 
bladders during chronic cystitis. I then leveraged these structural insights to develop novel small-
molecule galactosides that function as high-affinity competitive antagonists of FmlH with 
therapeutic efficacy in mouse models of UTI. Together, the work presented in this thesis provides 
fundamental, biophysical underpinnings of host-pathogen interactions in UTI and provides novel 
treatment modalities that may help reduce the economic and health burdens imposed by this 
















Conformational ensembles of FimH alleles 
 The type 1 pilus adhesin FimH binds mannosylated receptors on the bladder epithelium, 
mediates invasion of superficial facet cells, and promotes formation of tight-knit biofilm-like 
communities termed intracellular bacterial communities (IBCs), all critical to the establishment of 
UTIs by UPEC [1-7]. FimH has a mannose binding lectin domain (FimHLD) and a pilin domain 
(FimHPD), which is joined via DSE to the FimG pilin [8]. Structural snapshots of pilus assembly 
[9-12] have revealed two distinct conformations in FimH, which I refer to as a low-affinity T state 
and high-affinity R state. Functional assays have hinted that mannose binds tightly to the R state 
but weakly, if at all, to the T state [9, 13], raising the question as to how FimH in a tip, which is 
observed by crystallography to adopt the T state, manages to bind mannose in solution. While the 
mannose binding pocket of FimH is invariant in all clinical UPEC strains, natural variation occurs 
outside of the binding pocket with residues at positions 27, 62, and 163 under positive selection 
[14]. In particular, the A27V/V163A double mutation confers increased mannose binding in vitro 
but results in a 10,000-fold reduction in mouse bladder colonization 24 hours post infection (hpi) 
and an inability to form IBCs. Thus, the A27V/V163A double mutation revealed either the 
necessity of an unknown function of FimH or the requirement for the regulation of mannose 
binding for in vivo fitness. The observation that positions which lie far away from the mannose 
binding pocket can, by some allosteric mechanism, impact FimH-dependent functions in UPEC 
pathogenesis is profound, but was not well understood.  
These questions prompted the investigation of the structural and evolutionary basis for 
conformational allostery in FimH at the pilus tip. FimH alleles purified within a FimGNteH 
complex, which functioned as a tip-like setting, were interrogated by a battery of molecular 
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biophysics techniques, including X-ray crystallography, small-angle X-ray scattering, ion mobility 
mass spectrometry, and molecular dynamics. These methods revealed that FimH in a tip-like 
setting natively adopts a pre-existing two-state conformational equilibrium in solution comprised 
of a single low-affinity T conformation and multiple, dynamic high-affinity R conformations. 
Positively selected residues can influence the relative proportions of these conformations. With 
respect to FimH from UPEC strain UTI89 (defined as WT), A62S skews the equilibrium toward 
the low-affinity T state while A27V/V163A pushes the equilibrium toward the high-affinity R 
state. In addition, high affinity mannose analogs termed mannosides can shift the conformational 
ensembles of FimH toward the R state. Yet despite their high-affinity for the R state, mannosides 
can engage both the T and R states through distinct binding modes, in which mannoside can enter 
and dock onto the low-affinity, solvent-exposed binding pocket of the T state in a “vertical” 
orientation or tightly interact with the compressed binding loops of the R state in a “horizontal” 
orientation. Together, the conformational landscape and ligation states indicate FimH exists in a 
thermodynamic cycle whereby binding can possibly proceed through induced fit (apo T à bound 
T à bound R) or conformational selection (apo R à bound R) or a mixture of both. The 
contribution of these binding mechanisms for each FimH allele requires further exploration 
through detailed kinetic studies capable of resolving each of these apo and ligated FimH 
conformational states. Furthermore, the conformational flexibility and number of viable 
bound R conformations in FimH may increase the biophysical adaptability of type 1 pili while 
tethered to a surface in part to allow attached bacteria to resist urine flow while bound to the 
bladder epithelium but further work is required to demonstrate that entropic freedom in the bound 
R state influences bacterial persistence at the host-pathogen interface to function as a molecular 
tether. 
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Our work also revealed that FimH alleles skewed toward the T state (A62S) or toward the 
R state (A27V/V163A) exhibit defects in pathogenesis in a mouse model of UTI, suggesting that 
an equilibrium between T and R states is optimal for bladder colonization. The mechanism by 
which the bladder habitat selects against the high-affinity R state as early as 1 hour post infection 
remains unknown and requires further investigation. Some possible explanations for this 
pathogenesis defect include a slow rate of association of the R state under conditions of flow, an 
inhibitory property mediated by intact superficial facet cells of the bladder epithelium, or soluble 
decoy receptors in the urine that preferentially antagonize variants that favor the R state. Together, 
our data suggest that the T state may serve to temporarily mask the strong affinity that FimH has 
for mannose to avoid restrictive factors or properties native to the bladder habitat to initiate 
productive binding when engaging the host epithelium.  
Overall, in-depth analysis of sequence variation in a virulence factor expressed by clinical 
E. coli isolates critical for UTI led to the elucidation of fundamental principles underlying host-
pathogen interactions. The work presented herein exposes the biophysical basis for evolutionary 
pressures that selected specific residues in FimH for fitness in the urinary tract and the structural 
basis for mannose binding by FimH. The conformational phase space of FimH in solution and 
population shifts spurred by positively selected residues further provides a framework for 
understanding the structural basis of allosteric coupling between inter-domain interactions and 
mannose binding. Finally, mannosides demonstrate considerable promise in the treatment of UTI, 
especially given their ability to target both the low-affinity T and high-affinity R conformations 




Galactoside inhibition of FmlH during chronic cystitis 
In addition to type 1 pili, UPEC express the Fml/F9/Yde pilus tipped with the FmlH 
adhesin to bind the inflamed bladder epithelium that exists during chronic cystitis [15]. Chronic 
cystitis is characterized by long-term UPEC colonization of a chronically inflamed bladder 
epithelium that is hyperplastic and devoid of terminally differentiated superficial facet cells, likely 
due to inflammation induced mucosal wounding, increased urothelial turnover and unchecked 
bacterial replication [16]. FmlH specifically binds to Tn antigen which appears as part of the 
remodeled glycan profile of the mouse bladder epithelium during chronic cystitis. Consistent with 
this, FmlH provides a fitness advantage during chronic cystitis but not in acute cystitis due to its 
ability to bind to inflamed but not to naïve bladder tissue.  
Furthermore, FmlH binds to TF epitopes found in naïve kidney tissue, thus promoting 
UPEC colonization of the kidneys [15]. As such, FmlH may play a critical role in the development 
of pyelonephritis, which contributes to high rates of hospitalization, severe kidney morbidities, 
and mortality [17]. Interestingly, FmlH is upregulated in urines directly isolated from patients with 
UTI compared to expression during in vitro growth in media or normal urine, suggesting a host 
condition-specific induction of Fml pili [18]. Thus, FmlH represents a promising target for the 
development of anti-adhesive compounds for use in the treatment of UTI and in particular 
pyelonephritis.  
Structure-guided drug design directed the development of high-affinity galactoside 
inhibitors of FmlH. Initial biochemical screens led to the identification of o-nitrophenyl β-
galactoside (ONPG) as an early lead FmlH inhibitor. A FmlH-ONPG co-crystal structure then 
facilitated in silico virtual screening of all known galactose analogs against FmlH, providing 
structural insights for the rational design of novel galactosides specific for FmlH. ELISA-based 
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screening and iterative rounds of structure-guided drug design led to the discovery of numerous 
phenyl and biphenyl galactoside antagonists of FmlH, including our lead compound, a biphenyl 
N-acetyl-β-galactosamine 29β-NAc, which exhibits a KD of ~90 nM, a ~7,800-fold enhancement 
in binding affinity relative to D-galactose. The design strategy for 29β-NAc accounted for all the 
unique structural features of the binding pocket of FmlH, including: (i) the wide and solvent-
exposed nature of the binding pocket; (ii) the considerable distance of Loop 1 from Loop 2 and 
Loop 3; (iii) the capping of the binding pocket by residue Y46; (iv) the positively charged side 
chain of residue R142 on the edge of the binding pocket; and (v) the capacity to accommodate the 
N-acetyl group of N-acetyl galactosamine. Necessarily, FmlH galactoside design differed in 
approach to that of FimH mannoside design due to differences in receptor specificity, 
stereoisomerism at the anomeric carbon, binding affinity, binding pocket architecture, and 
accessory side chains in the vicinity of the binding pocket (including orientation of tyrosine 
residues). Yet, similarities in the properties of these compounds, including the biphenyl scaffold 
in the aglycone group and hydrogen bond interactions mediated through functional groups on the 
B ring, may be a reflection of universal features of adhesin-carbohydrate interactions and a 
common mechanism by which aromatic aglycones mimic those interactions.  
Our in vivo work clearly demonstrates the translational impact of galactosides as treatments 
for UTI. Transurethral delivery of 29β-NAc resulted in significant reduction of bacterial titers in 
the bladder and especially the kidney. Furthermore, a combinatorial approach in which both 29β-
NAc and mannoside 4Z269 were administered resulted in synergistic efficacy in ridding the kidney 
of UPEC, suggesting that FimH and FmlH occupy niches within the urinary tract simultaneously 
during chronic UTI. Future studies aim to further this progress in galactoside development through 
optimization of oral bioavailability, pharmacokinetics, and metabolic stability, which will provide 
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lead candidates that can be tested individually or together with mannosides for treatment or 
prevention of human cystitis and pyelonephritis in the clinic. 
 
Future directions 
FimH conformations in biofilm formation and maturation 
 Type 1 pili and FimH play a critical role in the formation and maturation of biofilms on 
abiotic surfaces [19]. Deletion of type 1 pili results in an attenuated ability of E. coli to mediate 
microcolony formation. Further, mannose or α-methyl-D-mannose can inhibit biofilm formation 
on diverse abiotic substrates, including polyvinyl chloride, polycarbonate, polystyrene, and 
borosilicate glass. A fascinating corollary exists between the propensity of E. coli to form biofilms 
and the mannose binding affinity and/or conformational state of FimH [14]. Yet, the mechanism 
by which FimH adsorbs to a surface and promotes biofilm formation among E. coli remains 
elusive. I hypothesize that the high-affinity R state is dually critical for biofilm formation: (i) for 
abiotic surface attachment with a hydrophobic surface of FimH exposed in the R state during 
biofilm initiation and (ii) for high-affinity mannose binding during biofilm expansion/maturation.  
To address this hypothesis, a two-pronged approach can be pursued. First, biofilm and 
hemagglutination screening can be performed on a FimH mutant library generated by error-prone 
PCR to identify mutation(s) that preserve the structure of FimH in the R state but prevents mannose 
binding. In addition, molecular dynamics simulations of FimH adsorption to a graphene sheet can 
reveal specific residues implicated in surface interactions that could then spur site-directed 
mutagenesis. Together, these studies could decouple surface adhesion from biofilm maturation and 
reveal the atomic basis for FimH-mediated biofilm formation, providing key molecular details for 
understanding and combatting biofilms that form on catheters and lead to serious nosocomial 
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infections. 
In vivo colonization resistance to high-affinity R state 
 UTI89 engineered to express A27V/V163A FimH, which predominantly occupies the 
high-affinity R state, lacks the ability to effectively colonize the urinary tract and establish UTI. I 
hypothesize that the high mannose binding affinity of A27V/V163A is directly responsible for its 
colonization defect. To uncover the mechanism which mediates this colonization resistance, we 
first examined whether Tamm-Horsfall protein (THP) is responsible for the pathogenesis defect of 
A27V/V163A. In a preliminary study, THP knock-out mice (of the 129S1 background) acquired 
from Dr. Satish Kumar were inoculated with 107 CFU/ml of UTI89 expressing either WT FimH 
or A27V/V163A FimH. Bacterial titer analysis indicates that A27V/V163A remains attenuated 
relative to WT FimH in this mouse model, suggesting that THP does not mediate the pathogenesis 
defect of A27V/V163A (Fig. 1). Further work will explore whether other decoy receptors on the 
surface of superficial facet cells or in urine, such as secretory IgA or soluble oligomannose, may 
be involved in mediating this pathogenesis defect. Mouse and human urine filtration experiments 
and outer membrane preparations of superficial facet cells derived from in vitro bladder spheroid 
models will provide the cleanest approaches to pulling down or identifying receptors that may be 
implicated in the colonization resistance property of the bladder habitat.  
SfaH structure-function relationship and biological tropism of S pili 
 E. coli expressing S pili have been implicated in the onset or maintenance of neonatal 
meningitis and UTI [20-23]. However, the role of S pili in infectious disease has not be clearly 
delineated. Moreover, the mechanism underlying the sialic acid specificity of S pili is not clearly 
understood. Several studies implicate different components of S pili with adhesive functions, with 
debates regarding the true adhesin [24, 25]. Some experimental evidence suggests that SfaG, a 
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pilus tip adapter, is responsible for recognition of sialic acid receptors while bioinformatics 
suggests that the SfaH adhesin would exert the function of sialic acid binding. Through a panel of 
glycan arrays, I have shown that SfaH in a SfaCH complex does not bind sialic acid residues or 
any other tested glycan structure (Fig. 2A-D). Yet, SfaH does possess some adhesive ability, as 
SfaH in a SfaCH complex strongly binds secretory IgA and laminin in a protease-sensitive manner, 
suggesting that SfaH may play a role in binding uncharacterized protein tertiary structures or 
motifs (Fig. 3). A crystal structure of SfaHLD indicates that it adopts a similar fold to FimH (Fig. 
4A), resembling FimHLD in the T conformation (RMSD=1.7 Å) more than FimHLD in the R 
conformation (RMSD=3.2 Å) (Fig. 4B-C). However, the side chain packing in the canonical 
binding pocket appears to restrict space necessary for carbohydrates to interact with SfaH, likely 
due to steric occlusion mediated by residues S14 and E148 (Fig. 4D). Thus, while SfaH closely 
resembles an adhesin homologous to FimH and FmlH, SfaH lacks the ability to bind glycans due 
to the geometry of residues within the canonical adhesin binding pocket that preclude the entrance 
of carbohydrate moieties. More work is required to demonstrate that SfaG is the true sialic acid 
binder within S pili through purification of SfaG and screening in glycan arrays and glycoprotein 
binding assays. Thereafter, the binding functions of SfaG and SfaH should be evaluated using 
immunohistochemistry methods against tissues at implicated host sites, such as meninges, choroid 
plexus, kidneys, and bladder, and of different host ages, including neonates and adults, to 
determine their role in pathogenesis.  
Conformational ensembles in CUP adhesins as a universal feature of bacterial adhesion 
 CUP pili typically present tip-localized two-domain adhesins to mediate attachment to a 
particular host or tissue. These two-domain adhesins are comprised of a lectin domain, which often 
recognizes a specific carbohydrate receptor, and a pilin domain, which anchors the adhesin to the 
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distal end of the pilus. FimH has been demonstrated to adopt diverse structures within a two-state 
conformational landscape, a property that may represent a universal feature of two-domain CUP 
adhesins. Ion mobility mass spectrometry analysis of FmlGNteH and SfaGNteH complexes reveal 
that these two homologs of FimH do in fact adopt a two-state conformational equilibrium similar 
in distribution to FimGNteH, lending support to the supposition that conformational phase space is 
a natural property of two-domain CUP adhesins (Fig. 5). Further studies will explore whether these 
two-state conformational equilibria in FmlH and SfaH impact ligand binding affinity and 
pathogenesis, as is observed in FimH. Future studies will also aim to investigate FimH homologs 
and related two-domain CUP adhesins among Gram-negative bacteria (Fig. 6) to characterize 
diverse conformational landscapes and receptor specificities to understand mechanisms underlying 
E. coli adhesion and tissue and host tropisms.  
 
Closing remarks 
Studies rooted in structural biology have uncovered fundamental physicochemical 
principles of the chaperone-usher pathway. Protein crystallography, in particular, has provided 
views of key macromolecular interactions at the host-pathogen interface at the atomic level. 
However, these static structures only serve as signposts for the dynamic processes that underlie 
CUP pilus function. This thesis builds on previous structural studies with a focus on a biophysical 
understanding of the allosteric and dynamic molecular details of CUP systems using a broad range 
of techniques including bacterial genetics, bioinformatics, computational biology, biochemistry, 
biophysics, structural biology, and cell biology. Understanding how protein-protein interactions 
and ligand binding can regulate a dynamic conformational equilibrium of the receptor binding 
domain of bacterial adhesins is changing the established view of UTI pathogenesis. Elucidating 
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structure-function relationships in distinct adhesins has helped build a molecular platform for 
interrogation and identification of host selective pressures that have acted to diversify ligand 
specificity and has contributed to the design of novel anti-virulence compounds for the treatment 
of UTI. Together, this work has unraveled the dynamics, allostery, and atomic determinants that 
govern CUP function and specificity, which is critical for understanding virulence in Gram-
negative pathogens and is spawning new ways of thinking about drug development for the 
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Figure 1. Role of THP in mediating colonization resistance to FimH variants. Bacterial titers in 
the bladders of THP knockout mice infected with 107 CFU/ml UTI89 expressing either WT FimH 
















Figure 2. Glycan array screens for determination of SfaH specificity. Biotinylated SfaCH complex 
(100-200 μg) was incubated with various glycan arrays, which include (A) the National Center for 
Functional Glycomics (NCFG) defined glycan array, (B) the NCFG modified sialyl glycan array, 
(C) the NCFG SBA glycan array, and (D) the Center for Functional glycomics (CFG) glycan array 
v5.2. Bound SfaCH was then quantitated after incubation of streptavidin labeled with Alexa Fluor 











Figure 3. Glycoprotein binding by SfaH. Glycoproteins (1 μg) coated on an ELISA plate, as 
indicated on the x-axis, were pre-treated either with PBS, sialidase, or trypsin for 1 hour at 37 ˚C. 
Thereafter, biotinylated SfaCH complex (5 μg) was incubated with glycoproteins for 4 hours at 4 













Figure 4. Structural analysis of SfaH. (A) Crystal structure of SfaHLD solved to a resolution of 1.6 
Å (Rwork=16.1%; Rfree=19.4%). (B) Structural overlay of SfaHLD (yellow) and FimHLD in the R 
conformation (marine). (C) Structural overlay of SfaHLD (yellow) and FimHLD in the T 
conformation (magenta). (D) Binding pocket of SfaHLD indicating the proximity between and 















Figure 5. Conformational ensembles of fimbrial adhesins. Ion mobility mass spectrometry reveals 
drift time distributions of adhesins in tip-like settings (GNteH complexes), including FmlGNteH WT, 
SfaGNteH WT, FimGNteH WT, FimGNteH Q133K, FimGNteH A62S, and FimGNteH A27V/V163A. 
These distributions indicate two distinct conformations centered around t=6 ms and t=7 ms. 
FimGNteH A27V/V163A, as expected, predominantly adopts a single conformation characterized 
by a drift time of 6 ms while all other tested adhesins display an equilibrium of two conformations 





Figure 6. Diversification of CUP adhesins. Maximum likelihood phenogram depicting the 
evolutionary relationship among FimH, FmlH, and SfaH homologs in Gram-negative bacteria. 
Distinct groupings of branches are annotated according to relatedness to the three aforementioned 
adhesins. 
